

**Official Title:** An Open-Label Extension Study of Continuing Treatment with Trofinetide for Rett Syndrome

**NCT Numbers:** NCT04776746

**Document Date:** 19 December 2022



## **CLINICAL STUDY PROTOCOL**

### **An Open-Label Extension Study of Continuing Treatment with Trofinetide for Rett Syndrome**

**Protocol Number:** ACP-2566-005

**Amendment 1**

**Original Protocol Date:** 11 September 2020

**Protocol Amendment 1 Date:** 19 December 2022

#### **Confidentiality Statement**

This protocol is the confidential information of Acadia Pharmaceuticals Inc. and is intended solely for the guidance of the clinical investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of Acadia Pharmaceuticals Inc.

## SPONSOR SIGNATURE PAGE

**Title:** An Open-Label Extension Study of Continuing Treatment with Trofinetide for Rett Syndrome

**Acadia Head of Rare Disease and External Innovation:**

[REDACTED]

Senior Vice President  
Head of Rare Disease and External  
Innovation & Chief Scientific Officer  
Acadia Pharmaceuticals Inc.

[REDACTED]

*See appended electronic signature page*

---

Signature

Date

**Acadia Study Lead:**

[REDACTED]

Vice President, Clinical Development  
Acadia Pharmaceuticals Inc.

[REDACTED]

*See appended electronic signature page*

---

Signature

Date

Signature Page for ACP-2566-005 Protocol Amendment 1

Approve	
---------	--

Approve	
---------	--

Signature Page for ACP-2566-005 Protocol Amendment 1

## DECLARATION OF INVESTIGATOR

I confirm that I have read the above protocol. I understand it, and I will work according to the moral, ethical, and scientific principles governing clinical research as set out in the principles of Good Clinical Practice, as required by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline E6 and as described in the United States (US) Code of Federal Regulations (CFR) 21 CFR parts 50, 54, 56, 312, and according to applicable local requirements.

### Confidentiality Statement

The confidential information in this document is provided to you as an Investigator or Consultant for review by you, your staff, and the applicable institutional review board/ethics committee. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without written authorization from the Sponsor.

### Principal Investigator

---

Signature

---

Date

---

Name (printed)

## PROTOCOL SYNOPSIS<sup>1</sup>

<b>Protocol Number</b>	ACP-2566-005	
<b>EudraCT Number</b>	Not applicable	
<b>Protocol Title</b>	An Open-Label Extension Study of Continuing Treatment with Trofinetide for Rett Syndrome	
<b>Name of Investigational Product</b>	Trofinetide oral solution	
<b>Indication</b>	Rett syndrome	
<b>Phase of Development</b>	3	
<b>Sponsor</b>	Acadia Pharmaceuticals Inc. [REDACTED]	
<b>Primary Objective</b>	<ul style="list-style-type: none"><li>To investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome</li></ul>	
	<b>Primary Endpoints</b>	<ul style="list-style-type: none"><li>Treatment-emergent adverse events (TEAEs)</li><li>Serious adverse events (SAEs)</li><li>Withdrawals due to adverse events (AEs)</li><li>Potentially clinically important changes in other safety assessments</li></ul>

---

<sup>1</sup> NOTE: In this protocol, as in FDA guidance documents, the use of the word "should" means that something is suggested or recommended, but not required. If something "may be" done, the meaning is that something is allowed, but not required. The terms "must" and "will" mean that something is required.

Exploratory Objectives	Exploratory Endpoints
<ul style="list-style-type: none"> <li>• To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome</li> <li>• To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome on overall ability to communicate</li> <li>• To investigate the benefit of long-term treatment with oral trofinetide on overall quality of life for girls and women with Rett syndrome</li> <li>• To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome on: <ul style="list-style-type: none"> <li>○ Hand function</li> <li>○ Ambulation and other gross motor skills</li> <li>○ Ability to communicate choices and preferences</li> <li>○ Ability to communicate verbally</li> </ul> </li> <li>• To investigate the efficacy of long-term treatment with oral trofinetide on a global assessment of the severity of illness in girls and women with Rett syndrome</li> <li>• To investigate the benefit of long-term treatment with oral trofinetide on the burden on caregivers of girls and women with Rett syndrome</li> <li>• To investigate the benefit of long-term treatment with oral trofinetide on the</li> </ul>	<ul style="list-style-type: none"> <li>• Rett Syndrome Behaviour Questionnaire (RSBQ) total score – change from Baseline to end of treatment visit</li> <li>• Clinical Global Impression–Improvement (CGI-I) Score at the Week 12 visit (assessing improvement from Baseline <u>of the antecedent Study ACP-2566-004</u>)</li> </ul> <p>Change from Baseline to end of treatment visit in:</p> <ul style="list-style-type: none"> <li>• Communication and Symbolic Behavior Scales-Developmental Profile™ Infant-Toddler Checklist – Social Composite Score (CSBS-DP-IT Social)</li> <li>• Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability (ICND) Scale</li> <li>• Rett Syndrome Clinician Rating of Hand Function (RTT-HF)</li> <li>• Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)</li> <li>• Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)</li> <li>• Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)</li> <li>• Clinical Global Impression–Severity (CGI-S)</li> <li>• Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (items 1-24)</li> </ul>

<p>impact of the disability on the child's and family's everyday life</p>	
<p><b>Number of Study Sites</b></p>	<p>Approximately 28 sites will participate in this study.</p>
<p><b>Number of Subjects Planned</b></p>	<p>The sample size of this open-label study is not determined based on statistical considerations. However, subjects enrolled in the present study are those who have completed the antecedent study, ACP-2566-004, and rolled over to the present study. Since approximately 180 subjects are to be enrolled in the ACP-2566-004 study and it is expected 85% of these subjects will complete Study ACP-2566-004 and rollover to the present study, the number of subjects in the present study will be approximately 153.</p>
<p><b>Test Product, Dose, and Administration</b></p>	<p>The subject's assigned dose for this study will be the final dose from the antecedent study.</p> <p>If the subject's weight at the Baseline visit of the present study or after 52 weeks in the present study, or thereafter puts them in a new weight category, the Investigator may decide to increase the dose to the dose associated with the new weight category.</p> <p>Study drug is administered twice a day, once in the morning and once in the afternoon or evening. There should be at least 8 hours between doses. The study drug may be given with or without food.</p> <p>Doses may be taken orally or administered by gastrostomy (G) tube (doses administered via gastrojejunal [GJ] tubes must be administered through the G-port).</p> <p>If the subject cannot tolerate administration of the full assigned dose (for example, if the subject experiences diarrhea), the Investigator may instruct the caregiver to reduce study drug to a dose as low as 3 g (15 mL) BID. In addition, up to 4 doses (in total, consecutive or non-consecutive) may be held for this reason.</p>
<p><b>Study Design</b></p>	<p>This is a multi-center, open-label, long-term study of trofinetide to monitor the safety and efficacy of continuing trofinetide therapy for subjects who previously completed a Phase 3 trofinetide treatment study. Subjects who complete the preceding open-label study (ACP-2566-004) will be eligible to enroll in the present study. The duration of participation for individual study subjects will be approximately 32 months, or less than 32 months if: 1) trofinetide becomes commercially available for the treatment of Rett syndrome or 2) if development of trofinetide for Rett syndrome is discontinued. The Sponsor may discontinue the study for any reason.</p>




	<p>Legally acceptable representatives (LARs)/subjects <b>must be</b> consented prior to the procedures being performed at the end of treatment (EOT) visit of the antecedent study. The EOT visit of the antecedent study will serve as the Baseline visit of the present study. The data gathered at the EOT visit of the antecedent study serves as the baseline data of the present study. The study will have two periods:</p> <ul style="list-style-type: none"> <li>• Treatment period: up to approximately 32 months</li> <li>• Safety follow-up period: 30 days</li> </ul> <p><b><u>Open-label Treatment Period</u></b></p> <p>Dosing is twice a day, once in the morning and once in the evening.</p> <p>In addition to the study drug dispensed at the Baseline visit, additional investigational product will be shipped directly to the subject. Confirmation of delivery to the subject will be made by a visiting nurse. Study drug shipment, return, and accountability will be performed in accordance with the drug distribution plan.</p> <p>Subjects will have assessments completed at Week 12, Week 52, Week 104, and Week 130. Assessments may be completed in the clinic or off-site at the discretion of the Principal Investigator.</p> <p><b><u>Safety Follow-up Period (30 [+4] Days)</u></b></p> <p>Subjects will receive a follow-up telephone or telemedicine call to assess safety 30 (+4) days after the last dose of study drug if they do not begin to take commercially marketed trofinetide within the 30 days after completing the study, or if they discontinue prematurely from the study.</p> <p>The study schematic is provided in <a href="#">Figure S-1</a>.</p> <p>The schedule of assessments is provided in <a href="#">Table S-1</a>.</p>
<b>Study Duration</b>	<p>The duration of the study will be up to approximately 32 months and there will be a safety follow-up period of 30 days after the EOT/early termination (ET) visit.</p> <p>The study completion date is defined as the date the final subject, across all sites, completes their final protocol-defined assessment (i.e., the final 30-day follow-up telephone call).</p>
<b>Main Criteria for Inclusion and Exclusion</b>	<p>To be eligible for this study, subjects must meet all of the inclusion criteria and none of the exclusion criteria.</p> <p><b>Inclusion Criteria:</b></p> <ol style="list-style-type: none"> <li>1. Informed consent prior to the conduct of any study procedures is required as follows:</li> </ol>

	<ol style="list-style-type: none"> <li>a. For subjects who are minors: written informed consent will be obtained from the legally acceptable representative (LAR). The subject should provide written or oral assent if deemed able by the Investigator. The process of obtaining informed consent will be conducted in accordance with institutional review board (IRB) or ethics committee (EC) policy and applicable local law.</li> <li>b. For subjects who are not minors: written informed consent will be obtained from the LAR or the subject if deemed able by the Investigator. If the subject is deemed not able to provide consent, the subject should provide written or oral assent if deemed able by the Investigator. The process of obtaining informed consent will be conducted in accordance with IRB or EC policy and applicable local law.</li> <li>c. The subject's caregiver must also provide written informed consent regarding their participation in the study prior to participating in any study procedures.</li> </ol> <ol style="list-style-type: none"> <li>2. Has completed the EOT visit of the antecedent trofinetide Study ACP-2566-004 (i.e., has completed 40 weeks)</li> <li>3. May benefit from continued treatment with open-label trofinetide in the judgment of the Investigator</li> <li>4. Can still swallow the study medication provided as a liquid solution or can take it by gastrostomy tube</li> <li>5. The subject's caregiver has sufficient language skills to complete the caregiver assessments</li> </ol> <p><b><i>Childbearing Potential</i></b></p> <ol style="list-style-type: none"> <li>6. Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter. If a subject is sexually active or becomes sexually active during the study, she must use 2 clinically acceptable methods of contraception (e.g., oral, intrauterine device [IUD], diaphragm plus spermicide, injectable, transdermal or implantable contraception) for the duration of the study and for at least 30 days thereafter. Subject must not be pregnant or breastfeeding.</li> </ol> <p><b>Exclusion Criteria:</b></p> <ol style="list-style-type: none"> <li>1. Began treatment with growth hormone during the antecedent study</li> <li>2. Began treatment with IGF-1 during the antecedent study</li> </ol>
--	--

	<ol style="list-style-type: none"> <li>3. Began treatment with insulin during the antecedent study</li> <li>4. Has developed a clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease)</li> <li>5. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study</li> <li>6. Has a clinically significant abnormality in vital signs at Baseline</li> <li>7. Has an average QTcF interval of &gt;450 ms on the Baseline ECG performed before the first dose of trofinetide is given in the present study (i.e., the ECG performed at the EOT visit of the antecedent study)</li> <li>8. Has developed a clinically significant ECG finding during the antecedent study</li> <li>9. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason</li> </ol>
<b>Optional Caregiver Interview</b>	Participation of caregivers in an interview is an optional component of the study. Caregivers will be interviewed by a 3 <sup>rd</sup> party central agency about the study subject's and caregivers' experience of treatment in trofinetide studies. Only caregivers who sign a separate informed consent will be interviewed. The results of caregiver interviews will be summarized. The caregiver interview will be administered at or before the final study visit (Week 130 [EOT/ET]).
<b>Sample Size Calculations</b>	Approximately 153 subjects will be enrolled in this study. The sample size is not based on statistical considerations but will depend on the number of subjects who transition into this open-label extension study from the antecedent study.
<b>Statistical Methods</b>	<p>The purpose of this study is to collect safety data from subjects exposed to trofinetide in this study. Exploratory objectives include assessment of efficacy outcome measures over time. No formal testing of hypotheses is planned; all outcomes will be summarized descriptively.</p> <p><b><u>Analysis Sets</u></b></p> <p>The Safety Analysis Set will include all subjects who received at least one dose of study drug in this study. This analysis set will be used for all safety as well as any descriptive efficacy analyses.</p>

	<p><b><u>Descriptive Statistics</u></b></p> <p>All endpoints will be summarized for the Safety Analysis Set.</p> <p>Data from the EOT visit procedures of Study ACP-2566-004 will be carried over as Baseline information in the present study, as applicable, except for CGI-I.</p> <p>Continuous measurement results will be reported using the number of subjects with data values, mean, standard error of the mean, median, standard deviation, minimum, and maximum. For each categorical outcome, the frequency and percentage of subjects in each category will be reported.</p> <p><b><u>Primary Analyses</u></b></p> <p>Adverse events will be classified into standard terminology using the Medical Dictionary for Regulatory Activities (MedDRA). All AEs will be listed and TEAEs will be summarized by system organ class and preferred term. A TEAE is defined as an AE that started after the first administration of study drug and no later than the last administration of study drug plus 30 days. Summaries by maximum severity and by relationship to study drug will also be provided. Serious TEAEs, fatal AEs, and TEAEs leading to discontinuation will also be summarized.</p> <p>Descriptive summary statistics for ECG, vital signs and body weight, and clinical laboratory parameters, including observed values and changes from Baseline, will be tabulated by timepoint. Additionally, categorical analyses will be conducted on the incidence of subjects with prolonged QTc intervals and changes in QTc intervals in accordance with International Council for Harmonisation (ICH) guidelines.</p> <p><b><u>Efficacy Analyses</u></b></p> <p>Descriptive summary statistics for RSBQ (absolute values and change from Baseline), CGI-I (absolute values, assessed by comparing to the status at Study ACP-2566-004 baseline), CGI-S, CSBS-DP-IT Social, each of the four Rett Syndrome Clinician Rating scales, RTT-CBI, and ICND Quality of Life score absolute values and change from Baseline will be summarized by timepoint.</p>
<b>Date</b>	19 December 2022

**Figure S-1                      Schematic of Study Design for ACP-2566-005**



**Table S–1 Schedule of Events and Assessments for Study ACP-2566-005**

Period	Baseline	Open-label Treatment Period				Safety Follow-up
Visit Frequency		Week 12	Week 52	Week 104	Week 130/EOT/ET	EOT/ET +30 days
Visit Number	1	2	3	4	5	
Visit window (days)	N/A	±7	±7	±7	+7	+4
Type of Visit <sup>a</sup>	Clinic or Off-site					Telephone or Telemedicine
Informed consent	X <sup>b</sup>					
Inclusion/exclusion criteria	X					
Physical examination <sup>a</sup>	X	X	X	X	X	
Vital signs <sup>c</sup>	X	X	X	X	X	
Height	X	X	X	X	X	
Weight <sup>a</sup>	X <sup>a</sup>	X	X	X	X	
12-lead electrocardiogram (ECG)	X <sup>d</sup>	X	X	X	X	
Clinical laboratory tests (hematology, chemistry)	X	X	X	X	X	
Urinalysis	X	X	X	X	X	
Serum pregnancy test <sup>e</sup>	X	X	X	X	X	
Rett Syndrome Behaviour Questionnaire (RSBQ)	X	X	X	X	X	
Clinical Global Impression–Improvement since Baseline of Study ACP-2566-004 (CGI-I) <sup>f</sup>	X	X				
Clinical Global Impression–Severity (CGI-S)	X	X	X	X	X	
Communication and Symbolic Behavior Scales-Developmental Profile™ Infant-Toddler (CSBS-DP-IT) Checklist	X		X	X	X	
Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability (ICND) Scale	X		X	X	X	
Rett Syndrome Clinician Rating of Hand Function (RTT-HF)	X	X	X	X	X	
Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)	X	X	X	X	X	
Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC) <sup>a</sup>	X	X	X		X	
Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)	X	X	X		X	
Rett Syndrome Caregiver Burden Inventory (RTT-CBI)	X		X		X	

*Table abbreviations and footnotes provided on next page*

**Table S–1 Schedule of Events and Assessments for Study ACP-2566-005  
(Continued)**

Period	Baseline	Open-label Treatment Period				Safety Follow-up
Visit Frequency		Week 12	Week 52	Week 104	Week 130/EOT/ET	EOT/ET +30 days
Visit Number	1	2	3	4	5	
Visit window (days)	N/A	±7	±7	±7	+7	+4
Type of Visit <sup>a</sup>	Clinic or Off-site					Telephone or Telemedicine
Dispensing and review of semi-structured caregiver diary, including seizure diary	X	X	X	X	X	
Concomitant medications	X	X	X	X	X	X
Assessment of adverse events	X	X	X	X	X	X
Optional caregiver interview <sup>g</sup>		X				
Study drug dispensed <sup>h</sup>	X					
Authorization of study drug dispensation <sup>h</sup>	X-----X					
Study drug return <sup>h</sup>	X-----X					
Study drug accountability <sup>h</sup>		X	X	X	X	

Abbreviations: EOT=end of treatment; ET=early termination

- <sup>a</sup> Assessments may be completed in the clinic or off-site, at the discretion of the Principal Investigator. When a study visit takes place off-site, the physical examination will not be required. Weight should be measured whenever possible at off-site visits. Measurement of weight is necessary at Baseline in order to determine the starting dose. The RTT-COMC should be completed if possible, but it is not required.
- <sup>b</sup> Consent for the present study **must be** obtained prior to performance of the EOT procedures at the EOT visit in the antecedent study. Data from the EOT visit procedures of the antecedent study will be carried over as Baseline information in the present study, as applicable.
- <sup>c</sup> Vital signs will include body temperature, resting respiration rate, sitting systolic and diastolic blood pressure, and pulse rate. The sitting blood pressure will be measured after the subject has been sitting for ≥3 minutes.
- <sup>d</sup> ECGs will be completed in triplicate at Visit 1 (Baseline) before dosing. The ECG taken at the EOT visit in the antecedent study is the Baseline ECG of the present study. A single ECG will be completed at all other designated visits.
- <sup>e</sup> For subjects who have reached menarche and have not had surgical sterilization
- <sup>f</sup> The CGI-I assessments for each post-Baseline visit will be assessing improvement from Baseline of the antecedent Study ACP-2566-004.
- <sup>g</sup> Caregiver interviews will be conducted remotely via telephone at or before the final study visit (Week 130 [EOT/ET]). Participation in the caregiver interview is an optional component of the study requiring a separate informed consent.
- <sup>h</sup> Investigational product will be shipped directly to the subject. Confirmation of delivery to the subject will be made by a visiting nurse. Study drug shipment, return, and accountability will be performed in accordance with the drug distribution plan. In addition, study drug will be dispensed at the site during the Baseline visit when the visit is conducted in the clinic.

## TABLE OF CONTENTS

SPONSOR SIGNATURE PAGE .....	2
DECLARATION OF INVESTIGATOR .....	4
PROTOCOL SYNOPSIS.....	5
TABLE OF CONTENTS.....	15
LIST OF TABLES .....	19
LIST OF FIGURES .....	19
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS.....	20
1 INTRODUCTION.....	22
1.1 Background Information .....	22
1.2 Investigational Product.....	23
1.3 Previous Clinical Experience .....	24
1.4 Study Rationale .....	27
2 STUDY OBJECTIVES AND ENDPOINTS.....	28
2.1 Primary Objective.....	28
2.1.1 Primary Endpoints .....	28
2.2 Exploratory Objectives.....	28
2.2.1 Exploratory Endpoints.....	29
3 STUDY DESCRIPTION.....	29
3.1 Overview of Study Design .....	29
3.1.1 Open-label Treatment Period.....	30
3.1.2 Safety Follow-Up Period (30 [+4] Days).....	31
4 SUBJECT ELIGIBILITY AND WITHDRAWAL CRITERIA.....	31
4.1 Inclusion Criteria.....	31
4.2 Exclusion Criteria.....	32
4.3 Subject Withdrawal of Consent.....	32
4.4 Subject or Study Discontinuation.....	33
4.4.1 Post-Baseline QTcF Interval Stopping Criteria.....	33
4.4.2 Handling of Subject Discontinuation During the Treatment Period .....	34
4.5 Subject Lost to Follow-Up .....	34
4.6 Concomitant Therapy .....	34



4.6.1	Permitted and Prohibited Medications .....	35
5	INVESTIGATIONAL PRODUCT .....	35
5.1	Investigational Product Description .....	35
5.1.1	Formulation, Appearance, and Packaging .....	35
5.1.2	Product Storage and Stability .....	36
5.1.3	Dosing and Administration .....	36
5.1.3.1	Dosing .....	36
5.1.3.2	Administration of Study Drug .....	37
5.1.4	Method of Assigning Subjects to Treatment Groups .....	37
5.1.5	Blinding .....	37
5.1.6	Study Drug Compliance .....	37
5.1.7	Overdose .....	37
5.2	Investigational Product Accountability Procedures .....	37
6	STUDY PROCEDURES .....	38
6.1	Efficacy Assessments .....	38
6.1.1	Rett Syndrome Behaviour Questionnaire (RSBQ) .....	38
6.1.2	Clinical Global Impression–Improvement (CGI-I) and Clinical Global Impression–Severity (CGI-S) .....	39
6.1.3	Communication and Symbolic Behavior Scales - Developmental Profile Infant-Toddler (CSBS-DP-IT) Checklist .....	40
6.1.4	The Quality of Life Rating of the Impact of Childhood Neurologic Disability (ICND) Scale .....	41
6.1.5	Rett Syndrome Clinician Rating of Hand Function (RTT-HF) .....	41
6.1.6	Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB) .....	41
6.1.7	Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC) .....	42
6.1.8	Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM) .....	42
6.1.9	Rett Syndrome Caregiver Burden Inventory (RTT-CBI) .....	42
6.2	Safety Assessments .....	43
6.2.1	Physical Examination .....	43
6.2.2	Vital Signs .....	43
6.2.3	Height, Weight, and Body Mass Index .....	43
6.2.4	Electrocardiograms .....	43
6.2.4.1	Post-Enrollment QTcF Interval Stopping Criteria .....	44
6.2.5	Laboratory Evaluations .....	44
6.3	Caregiver Diary .....	45
6.4	Caregiver Interview .....	45

7	ADVERSE EVENTS .....	46
7.1	Specification of Safety Parameters.....	46
7.1.1	Definition of Adverse Event.....	46
7.1.2	Definition of Serious Adverse Event.....	47
7.2	Classification of an Adverse Event .....	48
7.2.1	Severity of Event .....	48
7.2.2	Relationship to Study Drug .....	48
7.2.3	Duration.....	49
7.2.4	Frequency .....	49
7.2.5	Action Taken with Study Drug.....	49
7.2.6	Therapy.....	49
7.2.7	Outcome .....	50
7.2.8	Seriousness .....	50
7.2.9	Definition of Unexpectedness .....	50
7.3	Time Period and Frequency for Event Assessment and Follow-Up.....	50
7.4	Reporting Procedures .....	51
7.4.1	Adverse Event Reporting .....	51
7.4.2	Serious Adverse Event Reporting.....	51
7.4.3	Reporting of Pregnancy.....	52
7.4.4	Reporting of Overdose .....	52
8	CLINICAL MONITORING.....	53
9	STATISTICAL METHODS AND DATA ANALYSIS .....	53
9.1	Statistical and Analytical Plans .....	53
9.2	Statistical Hypotheses.....	53
9.3	Sample Size Determination.....	53
9.4	Subject Populations for Analysis.....	53
9.5	Statistical Analyses.....	53
9.5.1	General Approach.....	53
9.5.2	Primary Analyses.....	54
9.5.3	Efficacy Analyses .....	54
9.5.4	Subgroup Analyses .....	54
9.6	Interim Analyses.....	54
9.7	Measures to Minimize Bias.....	54
9.8	Breaking the Study Blind/Subject Code.....	54
10	STUDY MANAGEMENT AND DATA COLLECTION .....	55

10.1	Data Collection and Management Responsibilities.....	55
10.2	Source Documents.....	55
10.3	Case Report Forms .....	55
10.4	Confidentiality.....	55
10.5	Study Records Retention.....	56
10.6	Protocol Exceptions and Deviations.....	56
10.7	Protocol Amendments .....	56
11	QUALITY MANAGEMENT .....	57
11.1	Risk Management.....	57
11.2	Quality Control and Quality Assurance.....	57
12	ETHICAL CONSIDERATIONS.....	58
12.1	Ethical Standard .....	58
12.2	Institutional Review Board/Ethics Committee.....	58
12.3	Informed Consent Process.....	59
12.3.1	Consent and Other Informational Documents Provided to Subjects.....	60
12.3.2	Consent Procedures and Documentation.....	60
13	PUBLICATION PLAN .....	61
14	CONFLICT OF INTEREST POLICY .....	61
14.1	Finance, Insurance, and Indemnity.....	61
15	LITERATURE REFERENCES.....	62

## LIST OF TABLES

Table S–1	Schedule of Events and Assessments for Study ACP-2566-005 .....	13
Table 1–1	Change from Treatment Baseline (Day 14) to End of Treatment (Day 54) in Core Efficacy Outcomes (mITT) (Neu-2566-RETT-002) .....	25
Table 5–1	Weight-Dosing Categories .....	36

## LIST OF FIGURES

Figure S–1	Schematic of Study Design for ACP-2566-005 .....	12
Figure 1–1	Comparison of Change from Treatment Baseline on the RSBQ at Follow-Up Assessments Between 200 mg/kg BID and Placebo BID Treatment Groups .....	26

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

Term	Definition
AE	adverse event(s)
AUC <sub>0-12ss</sub>	area under the blood concentration-time curve from 0 to 12 hours
BID	twice daily
CFR	Code of Federal Regulations
CGI-I	Clinical Global Impression–Improvement
CGI-S	Clinical Global Impression–Severity
C <sub>max</sub>	maximum observed drug concentration
CSBS-DP-IT	Communication and Symbolic Behavior Scales-Developmental Profile™ Infant-Toddler Checklist
EC	ethics committee
ECG	electrocardiogram
eCRF	electronic case report form
EOT	end of treatment
ET	early termination
EU GDPR	European Union General Data Protection Regulation
GCP	Good Clinical Practice
GJ	gastrojejunal
GPE	glycine-proline-glutamate
ICF	informed consent form
ICH	International Council for Harmonisation
ICND	Impact of Childhood Neurologic Disability Scale
IGF-1	insulin-like growth factor 1
IRB	institutional review board
LAR	legally acceptable representative
MeCP2	methyl-CpG binding protein 2
<i>MeCP2</i>	gene encoding methyl-CpG binding protein 2 (in animals)
<i>MECP2</i>	gene encoding methyl-CpG binding protein 2 (in humans)
PK	pharmacokinetic
PR interval	PR interval of ECG
QRS interval	QRS interval of ECG
QT interval	QT interval for heart rate of ECG
QTc	corrected QT interval of ECG for heart rate
QTcB	corrected QT interval using Bazett's correction method
QTcF	corrected QT interval using Fridericia's correction method
RSBQ	Rett Syndrome Behaviour Questionnaire

<b>Term</b>	<b>Definition</b>
RTT	Rett syndrome
RTT-AMB	Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills
RTT-CBI	Rett Syndrome Caregiver Burden Inventory
RTT-COMC	Rett Syndrome Clinician Rating of Ability to Communicate Choices
RTT-DSC	RTT Domain Specific Visual Analog Scale
RTT-HF	Rett Syndrome Clinician Rating of Hand Function
RTT-VCOM	Rett Syndrome Clinician Rating of Verbal Communication
SAE	serious adverse event(s)
TEAE	treatment emergent adverse event(s)
US	United States

## 1 INTRODUCTION

This document is a research protocol and the described study will be conducted in compliance with the protocol and the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline.

### 1.1 Background Information

Rett syndrome (RTT) is a seriously debilitating neurodevelopmental disorder for which there is currently no approved treatment. Its prevalence is reported as 1 in 10,000-15,000 female live births (Bienvenu et al. 2006; Neul et al. 2010). While the great majority of patients with RTT are females, males who meet the criteria for RTT have also been identified (Neul et al. 2019). In 96-98% of patients diagnosed with classic RTT, the disease is caused by mutations in the X-linked *MECP2* gene (Percy et al. 2018). *MECP2* encodes methyl-CpG binding protein 2 (MeCP2) which modulates gene expression by binding to methylated CpG dinucleotides, primarily by activating but also by repressing transcription (Ip et al. 2018; Neul et al. 2008; Kriaucionis and Bird 2003; Hite et al. 2009). The activity of the MeCP2 protein is diminished in both neurons and astrocytes (Yasui et al. 2013).

In patients with typical RTT, there is seemingly normal psychomotor development for the first 6 months of life, but soon thereafter the failure to reach normal developmental milestones is observed, followed by a period of developmental regression in which there is a loss of normal use of the hands and of spoken language (Samaco and Neul 2011). The period of developmental regression is accompanied by transient autistic features in many but not all individuals with RTT (Lee et al. 2013; Neul et al. 2014). Loss of social skills appears to stabilize or reverse after the regression period, and individuals with RTT demonstrate social intentions through eye contact (Young et al. 2008; Djukic and McDermott 2012; Urbanowicz et al. 2016). Nonetheless, social interaction and communication remain limited (Mount et al. 2003; Urbanowicz et al. 2015; Rose et al. 2013; Kaufmann et al. 2012; Woodyatt and Ozanne 1993). The intellectual disability in RTT appears to be profound; however, precise measurement of the extent of cognitive impairment is difficult because of the severe communication and motor deficits affecting most individuals (Byiers and Symons 2012; Clarkson et al. 2017).

Seizures are common, although not diagnostic. Commonly observed symptoms include awake breathing disruptions, scoliosis, and interest in social interaction (intense eye communication) (Neul et al. 2010; Percy et al. 2010). Gastrointestinal symptoms, including constipation and chewing and swallowing difficulties, are observed in the majority of patients with RTT (Motil et al. 2012). Sudden changes in mood, screaming and inconsolable crying are common behaviors in children and adolescents with RTT (Mount et al. 2001, 2002; Robertson et al. 2006; Cianfaglione et al. 2015). These impairments can further exacerbate

other symptoms and disrupt activities of daily living including educational, recreational and treatment opportunities (Epstein et al. 2016; Perry et al. 1991; Thompson and Iwata 2001; Iemmi et al. 2016). Autonomic manifestations, which include abnormalities in cardiac and respiratory function, as well as in peripheral circulation, are considered to be predominantly of central nervous system origin. Rett syndrome is also characterized by impaired growth affecting the brain and other organ systems.

Loss of purposeful hand use is a defining aspect of RTT during the onset of regression and at least 30% of individuals remain without any type of purposeful hand use (Downs et al. 2010). Individuals with some purposeful hand movements vary in their level of ability to reach for and grasp objects. The ability to self-feed is observed in 25-43% (Cass et al. 2003; Larsson et al. 2005; Downs et al. 2011). Poorer levels of hand function are associated with both age and severity of mobility impairment (Downs et al. 2011).

In adulthood, a late motor deterioration stage occurs, characterized by worsening dystonia, rigidity, and in some cases deterioration in the ability to walk and parkinsonian symptoms. Affected individuals have a yearly death rate between 1% and 2%, with 25% of all deaths characterized as sudden and unexpected (Kerr et al. 1997; Samaco and Neul 2011). Women with RTT can survive into their fifties and occasionally longer (Samaco and Neul 2011).

There are no medicines approved for the treatment of RTT. Treatment focuses on the management of each patient's symptoms and, even in that regard, is often unsatisfactory and has only a limited effect on functional improvement. Accordingly, the burden on families and other caregivers is very great (Palacios-Ceña et al. 2018).

## 1.2 Investigational Product

Trofinetide is a synthetic analog of glycine-proline-glutamate (also known as glypromate or GPE), a peptide that occurs naturally in the brain. GPE is the *N*-terminal tripeptide of the insulin-like growth factor 1 (IGF-1) protein. Trofinetide crosses the blood-brain barrier following oral administration. In the brain, it is believed to normalize decreased bioavailability of IGF-1 and GPE, as well as having an anti-inflammatory effect on pathologically activated glial cells. Both conditions contribute to deficits in synaptic development and functional maturation of synaptic plasticity that are fundamental to the wide-ranging effects of RTT. Tropea et al. (2009) observed that treatment with GPE reversed Rett-like symptoms in *MeCP2* mutant mice. Therefore, the aim of treatment with trofinetide is to exert an effect on brain structure and function such as dendritic length and branching and long-term potentiation, which would be expected to lead to improvements across a wide range of symptoms of RTT.



### 1.3 Previous Clinical Experience

Trofinetide showed linear pharmacokinetics (PK) across the dose range tested in pediatric RTT patients. These PK results are in agreement with the data obtained previously in healthy subjects and in adult RTT patients. From a drug metabolism perspective, there was no accumulation, metabolic inhibition, or induction observed during treatment. For subjects treated with 50 mg/kg twice daily (BID), median maximum (peak) observed drug concentration ( $C_{\max}$ ) was 17.7  $\mu\text{g/mL}$  and median  $\text{AUC}_{0-12\text{ss}}$  was 139.4  $\mu\text{g/mL}\cdot\text{h}$ . For subjects treated with 100 mg/kg BID, median  $C_{\max}$  was 52.6  $\mu\text{g/mL}$  and median  $\text{AUC}_{0-12\text{ss}}$  was 338.6  $\mu\text{g/mL}\cdot\text{h}$ . For subjects treated with 200 mg/kg BID, median  $C_{\max}$  was 82.2  $\mu\text{g/mL}$  and median  $\text{AUC}_{0-12\text{ss}}$  was 505.1  $\mu\text{g/mL}\cdot\text{h}$ . The geometric mean of the apparent terminal elimination half-life ( $t_{1/2}$ ) varied from 5.3 h to 6.1 h across the three dosing groups.

Trofinetide has exhibited a favorable safety and tolerability profile in two studies in subjects with Rett syndrome. Study Neu-2566-Rett-001 (NCT01703533) was a Phase 2 study of trofinetide in 56 adolescent and adult females with RTT ([Glaze et al. 2017](#)). Subjects were randomized 2:1 to 35 mg/kg trofinetide BID or placebo for 14 or 28 days (Cohorts 0 and 1, respectively) or 70 mg/kg trofinetide BID or placebo for 28 days (Cohort 2). Both dose levels were well-tolerated in this study, and no time- or dose-dependent adverse events (AEs) were apparent. The most common AE across all treatment groups was diarrhea (39% in the combined 35 mg/kg BID group, 11% in the 70 mg/kg BID group and 15% in the placebo group). The most common AE in the 70 mg/kg BID group was somnolence (17%; vs. 5% in the placebo group and 0% in the 35 mg/kg BID group). Four serious adverse events (SAEs) involving three subjects were reported during the study. In each of these instances, the AEs were deemed unrelated to the study medication. One subject withdrew from the study due to these events while the two subjects had already finished the study medication when their SAEs occurred. Each of these SAEs was deemed to be resolved by study conclusion. The results of this study also provided preliminary evidence of a treatment effect in the 70 mg/kg BID treatment group.

A second Phase 2 study of oral trofinetide in pediatric and adolescent females with RTT, Study Neu-2566-RETT-002, assessed three dose levels of trofinetide (50 mg/kg BID, 100 mg/kg BID, and 200 mg/kg BID vs. placebo) ([Glaze et al. 2019](#)). The study population consisted of female subjects between 5 and 15 years of age with a diagnosis of RTT and a proven mutation of the *MECP2* gene. The primary analysis of efficacy was change from treatment Baseline (Visit 3, Day 14, end of placebo run-in) to End-of-Assessment (Visit 7, Day 54) between placebo and the 200 mg/kg BID treatment groups.

At the time the study was initiated, there was no consensus upon the most appropriate and sensitive endpoint(s) for detecting beneficial drug effect in RTT, so the study examined five

unranked core efficacy outcome measures. Each of these five endpoints represented a different dimension or manifestation of the pathophysiology and clinical impairment directly associated with RTT. As shown below in Table 1–1, three of the five core endpoints showed a statistically significant difference from placebo at  $p < 0.05$  for the 200 mg/kg BID dose group: two clinician completed assessments (RTT Domain Specific Visual Analog Scale [RTT-DSC] and Clinical Global Impression–Improvement [CGI-I]) and one of the caregiver completed assessments (RSBQ). The remaining two primary endpoints were directionally positive.

**Table 1–1**                      **Change from Treatment Baseline (Day 14) to End of Treatment (Day 54) in Core Efficacy Outcomes (mITT)**  
**(Neu-2566-RETT-002)**

Outcome Measure	Prespecified covariates $p \leq 0.1$	Placebo (n=24)	50 mg/kg (n=15)	100 mg/kg (n=16)	200 mg/kg (n=27)
<b>RSBQ Total</b> D14 Treatment Baseline Change D14-D54 (LS mean) p-value vs. placebo <sup>a</sup>	PR	39.5 -2.3	44.7 -3.0 0.768	40.3 -1.5 0.749	42.2 -6.7 <b>0.042</b>
<b>RTT-DSC Total</b> <i>Exact Median Test</i> D14 Treatment Baseline Change D14-D54 p-value vs. placebo <sup>a</sup>	UnAdj	473.3 -25.85	450.0 -32.50 0.999	445.3 -12.10 0.748	516.6 -76.00 <b>0.025</b>
<b>CGI-I</b> D14 Treatment Baseline Change D14-D54 (LS mean) p-value vs. placebo <sup>b</sup>	UnAdj	(4) 3.5	(4) 3.3 0.391	(4) 3.4 0.703	(4) 3.0 <b>0.029</b>
<b>Top 3 Caregiver Concerns</b> D14 Treatment Baseline Change D14-D54 (LS mean) p-value vs. placebo <sup>a</sup>	UnAdj	223.8 -12.52	237.6 -16.56 0.776	211.5 -2.09 0.455	245.9 -18.54 0.619
<b>MBA Total</b> D14 Treatment Baseline Change D14-D54 (LS mean) p-value vs placebo <sup>a</sup>	TBL, PR	48.8 -2.6	46.6 -2.8 0.872	48.6 -2.4 0.925	46.6 -2.9 0.840

Abbreviations: CGI-I=Clinical Global Impression–Improvement; LS =least squares; MBA=Motor Behavior Assessment; mITT=modified Intent-to-treat; PR=placebo response; RSBQ=Rett Syndrome Behaviour Questionnaire; RTT-DSC=RTT Domain Specific Visual Analog Scale; TBL=treatment Baseline; UnAdj=unadjusted

<sup>a</sup> Prespecified model covariates if  $p \leq 0.1$ : TBL and/or PR.


<sup>b</sup> CGI-I has no pretreatment baseline value. The CGI-I values at Day 14 are the ratings of change from Day 0 (the pretreatment Baseline) to Day 14 (end of placebo run-in).

Among the three outcome measures that exhibited improvement compared to placebo for the 200 mg/kg BID group, the median magnitude of effect (change) was 15% for RTT-DSC (vs. 5% for placebo) and the mean magnitude of effect (change) was 16% for RSBQ (vs. 6%

for placebo). For the CGI-I, the mean outcome was 3.0 for the 200 mg/kg BID group and was 3.5 for placebo. For the CGI-I, more than 20% of subjects in the 200 mg/kg BID group were judged by clinicians to be “much improved”, compared with less than 5% of those on placebo.

At the end of the dosing period, data indicate that clinical benefit (change from treatment Baseline) was continuing to accrue and that there was a divergent trend between the placebo and 200 mg/kg BID groups as highlighted below in Figure 1–1 for the RSBQ. Further, there is evidence of a significant diminution of effect following cessation of dosing, suggesting that the separation during the dosing period was due to beneficial treatment effect and not from other differences between the two arms that occurred simply by chance.

**Figure 1–1 Comparison of Change from Treatment Baseline on the RSBQ at Follow-Up Assessments Between 200 mg/kg BID and Placebo BID Treatment Groups**



Abbreviations: BID=twice daily; LS=least squares; RSBQ=Rett Syndrome Behaviour Questionnaire  
Note: End of treatment assessment is at Day 54. Treatment baseline is at Day 14, at the end of the placebo run-in. Day 66 is post-treatment.

Trofinetide was generally safe and well tolerated. Most AEs reported during the double-blind treatment period were mild in intensity and the majority of events were deemed not related to study medication. The most common AEs reported from the start of the double-blind period across all treatment groups were diarrhea (27%), vomiting (15%), upper respiratory tract pyrexia (13%), and infection (12%). The most common AE from the start of the double-blind treatment period in the trofinetide treatment groups was diarrhea (27% in the 50 mg/kg BID group, 13% in the 100 mg/kg BID group, and 56% in the 200 mg/kg BID group compared

with 4% in the placebo group). The diarrhea associated with trofinetide may have been due to an improvement in gastrointestinal motility added to ongoing treatment with laxatives. Only three subjects experienced SAEs: one subject in the placebo BID group had an SAE of pneumonia, one subject in the 100 mg/kg BID group had an SAE of worsening of tonic cluster seizures, and one subject in the 200 mg/kg BID group had SAEs of streptococcal infection and pneumonia. In each of these instances, the SAEs were deemed not related to study medication and resolved by the end of the study.

No changes in QTc interval attributable to treatment were seen in adolescent and adult subjects with RTT in study Neu-2566-RETT-001, nor in pediatric subjects in Neu-2566-Rett-002.

Phase 2 studies of the oral formulation of trofinetide in adolescent and adult subjects with fragile X syndrome and of the intravenous formulation in adult subjects with moderate to severe traumatic brain injury (TBI) have also been completed and are described in the Investigator's brochure.

Always refer to the latest version of the trofinetide Investigator's Brochure for the overall benefit/risk assessment and the most accurate and current information regarding drug metabolism, PK, efficacy, and safety.

## **1.4 Study Rationale**

As described above, Rett syndrome is a devastating disorder for which there is as yet no treatment beyond symptomatic care resulting in a great unmet medical need. In the two studies of trofinetide in girls and women with RTT, trofinetide has been well tolerated. The highest dose assessed, 200 mg/kg BID, was observed to provide benefit compared to placebo even in a relatively small study, as described above. The Acadia-sponsored Study ACP-2566-003 is a 12-week, placebo-controlled study of the efficacy and safety of treatment with trofinetide for Rett syndrome. Subjects who complete study ACP-2566-003 may be eligible to enter Study ACP-2566-004, a 40-week, open-label study of trofinetide.

Some subjects will complete subject Study ACP-2566-004 before the earliest possible time at which trofinetide could become commercially available. The present study is an open-label study giving subjects who have completed ACP-2566-004 the opportunity to continue to receive open-label treatment with trofinetide until it becomes commercially available in the US. It is estimated that a 30-month study will provide enough time after the first subject completes Study ACP-2566-004 until trofinetide is available, or until it becomes apparent that trofinetide will not be marketed in the US.

## **2 STUDY OBJECTIVES AND ENDPOINTS**

### **2.1 Primary Objective**

The primary objective of this study is to investigate the safety and tolerability of continued long-term treatment with oral trofinetide in girls and women with Rett syndrome.

#### **2.1.1 Primary Endpoints**

The primary endpoints are:

- Treatment-emergent adverse events (TEAEs)
- Serious adverse events (SAEs)
- Withdrawals due to AEs
- Potentially clinically important changes in other safety assessments

### **2.2 Exploratory Objectives**

The exploratory objectives are:

- To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome.
- To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome on overall ability to communicate
- To investigate the benefit of long-term treatment with oral trofinetide on overall quality of life for girls and women with Rett syndrome
- To investigate the efficacy of long-term treatment with oral trofinetide in girls and women with Rett syndrome on:
  - Hand function
  - Ambulation and other gross motor skills
  - Ability to communicate choices and preferences
  - Ability to communicate verbally
- To investigate the efficacy of long-term treatment with oral trofinetide on a global assessment of the severity of illness in girls and women with Rett syndrome
- To investigate the benefit of long-term treatment with oral trofinetide on the burden on caregivers of girls and women with Rett syndrome
- To investigate the benefit of long-term treatment with oral trofinetide on the impact of the disability on the child's and family's everyday life

### 2.2.1 Exploratory Endpoints

The exploratory endpoints for this study are:

- Rett Syndrome Behaviour Questionnaire (RSBQ) total score – change from Baseline to end of treatment visit
- Clinical Global Impression–Improvement (CGI-I) Score at the Week 12 visit (assessing improvement from Baseline of the antecedent Study ACP-2566-004)

Change from Baseline to end of treatment visit in:

- Communication and Symbolic Behavior Scales-Developmental Profile™ Infant-Toddler Checklist – Social Composite Score (CSBS-DP-IT Social)
- Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability (ICND) Scale
- Rett Syndrome Clinician Rating of Hand Function (RTT-HF)
- Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)
- Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)
- Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)
- Clinical Global Impression–Severity (CGI-S)
- Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (items 1-24)

## 3 STUDY DESCRIPTION

### 3.1 Overview of Study Design

This is a multi-center, open-label, long-term study of trofinetide to monitor the safety and efficacy of continuing trofinetide therapy for subjects who previously completed a Phase 3 trofinetide treatment study. Subjects who complete the preceding open-label study (ACP-2566-004) will be eligible to enroll in the present study.

The duration of participation for individual study subjects will be approximately 32 months, or less than 32 months if: 1) trofinetide becomes commercially available for the treatment of Rett syndrome or 2) if development of trofinetide for Rett syndrome is discontinued. The Sponsor may discontinue the study for any reason. Note that not all subjects entering the present study will be treated for 32 months. It is anticipated that the time from which the *first* subject enters the present study until the predicted time that trofinetide receives marketing authorization and is marketed will be 29 months. Therefore, subjects who enter the present

study, for example, 6 months after the first subject enters, will receive treatment with trofinetide for approximately 23 months before the study is terminated based on the anticipated date of commercial availability of trofinetide.

Legally acceptable representatives (LARs)/subjects **must be** consented prior to the procedures being performed at the end of treatment (EOT) visit of the antecedent study. The EOT visit of the antecedent study will serve as the Baseline visit of the present study. The data gathered at the EOT visit of the antecedent study serves as the baseline data of the present study.

The duration of participation for individual study subjects will be up to approximately 32 months with a safety follow-up period of 30 (+4) days. Approximately 28 sites will participate in this study.

The study will have two periods ([Figure S-1](#)):

- Treatment period: up to approximately 32 months
- Safety follow-up period: 30 days

The schedule of events and assessments is provided in [Table S-1](#). As shown in the schedule of events, study visits may be done off-site rather than in the clinic, where appropriate and applicable.

The study completion date is defined as the date the final subject, across all sites, completes their final protocol-defined assessment. An individual subject is considered to have completed the study on the date of her final protocol-defined assessment. Please note that the “final protocol-defined assessment” includes the follow-up visit or contact, whichever is later. Procedures for when a subject is lost to follow-up are provided in [Section 4.5](#).

### **3.1.1 Open-label Treatment Period**

The EOT visit of the antecedent trofinetide study (e.g., ACP-2566-004) serves as the Baseline visit (Visit 1) of the present study. The day the first dose is taken will be considered Day 1 of dosing. Dosing is twice a day, once in the morning and once in the evening.

The dose will be administered and dose changes made according to [Section 5.1.3](#).

In addition to the study drug dispensed at the Baseline visit, additional investigational product will be shipped directly to the subject. Confirmation of delivery to the subject will be made by a visiting nurse. Study drug shipment, return, and accountability will be performed in accordance with the drug distribution plan.

Subjects will have assessments completed at Week 12, Week 52, Week 104, and Week 130. Assessments may be completed in the clinic or off-site, at the discretion of the Principal Investigator.

### **3.1.2 Safety Follow-Up Period (30 [+4] Days)**

A 30 (+4) day safety follow-up telephone or telemedicine contact is to be completed for subjects if they do not begin to take commercially marketed trofinetide within the 30 days after completing the study or if they discontinue prematurely from the study. The contact includes assessment of concomitant medications and treatments and assessment of AEs.

## **4 SUBJECT ELIGIBILITY AND WITHDRAWAL CRITERIA**

To be eligible for this study, subjects must meet all of the inclusion criteria and none of the exclusion criteria.

### **4.1 Inclusion Criteria**

A subject must meet all of the following inclusion criteria to be eligible for participation in the study:

1. Informed consent prior to the conduct of any study procedures is required as follows:
  - a. For subjects who are minors: written informed consent will be obtained from the legally acceptable representative (LAR). The subject should provide written or oral assent if deemed able by the Investigator. The process of obtaining informed consent will be conducted in accordance with institutional review board (IRB) or ethics committee (EC) policy and applicable local law.
  - b. For subjects who are not minors: written informed consent will be obtained from the LAR or the subject if deemed able by the Investigator. If the subject is deemed not able to provide consent, the subject should provide written or oral assent if deemed able by the Investigator. The process of obtaining informed consent will be conducted in accordance with IRB or EC policy and applicable local law.
  - c. The subject's caregiver must also provide written informed consent regarding their participation in the study prior to participating in any study procedures.
2. Has completed the EOT visit of the antecedent trofinetide Study ACP-2566-004 (i.e., has completed 40 weeks)
3. May benefit from continued treatment with open-label trofinetide in the judgment of the Investigator
4. Can still swallow the study medication provided as a liquid solution or can take it by gastrostomy tube



5. The subject's caregiver has sufficient language skills to complete the caregiver assessments

### ***Childbearing Potential***

6. Subjects of childbearing potential must abstain from sexual activity for the duration of the study and for at least 30 days thereafter. If a subject is sexually active or becomes sexually active during the study, she must use 2 clinically acceptable methods of contraception (e.g., oral, intrauterine device [IUD], diaphragm plus spermicide, injectable, transdermal or implantable contraception) for the duration of the study and for at least 30 days thereafter. Subject must not be pregnant or breastfeeding.

## **4.2 Exclusion Criteria**

A subject must meet none of the following exclusion criteria to be eligible for the study:

1. Began treatment with growth hormone during the antecedent study
2. Began treatment with IGF-1 during the antecedent study
3. Began treatment with insulin during the antecedent study
4. Has developed a clinically significant cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory, or gastrointestinal disease (such as celiac disease or inflammatory bowel disease)
5. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study, due to AEs, medical condition, or noncompliance with investigational product or study procedures in the antecedent study
6. Has a clinically significant abnormality in vital signs at Baseline
7. Has an average QTcF interval of >450 ms on the Baseline ECG performed before the first dose of trofinetide is given in the present study (i.e., the ECG performed at the EOT visit of the antecedent study)
8. Has developed a clinically significant ECG finding during the antecedent study
9. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason

## **4.3 Subject Withdrawal of Consent**

In accordance with the Declaration of Helsinki and other applicable regulations, a subject and LAR consenting on behalf of a subject have the right to withdraw from the study at any time, and for any reason, without prejudice to her future medical care.

Should a subject (or LAR) request or decide to withdraw consent, every reasonable effort will be made to complete and report observations as thoroughly as possible up to the date of withdrawal, including the evaluations specified at early termination (ET) or safety follow-up (whichever is applicable), as outlined in [Table S-1](#).

#### **4.4 Subject or Study Discontinuation**

Subjects may be discontinued from the study for a number of reasons, including, but not limited to, those listed below:

- Adverse event
- Death
- Increase in post-enrollment QTcF interval (defined below and in [Section 6.2.4.1](#))
- Lack of efficacy
- Lost to follow-up ([Section 4.5](#))
- Non-compliance with study drug
- Physician decision
- Pregnancy
- Protocol deviation
- Study terminated by sponsor
- Use of prohibited medication
- Other

The Sponsor reserves the right to discontinue the study at any time for any reason. Such reasons may be any of, but not limited to, the following:

- Occurrence of AEs unknown to date in respect of their nature, severity, and duration or the unexpected incidence of known AEs
- Medical, ethical or business reasons affecting the continued performance of the study

Regulatory authorities also have the right to terminate the conduct of the study in their region for any reason.

##### **4.4.1 Post-Baseline QTcF Interval Stopping Criteria**

Study drug must be discontinued in the event that a post-enrollment QTcF duration of  $\geq 500$  ms or an increase of  $\geq 60$  ms compared to the average QTcF interval at Baseline of the present study (before dosing) is observed. For visits at which more than one ECG is

completed, the average QTcF interval of all legible ECGs will be used to determine the QTcF interval for that visit.

#### **4.4.2 Handling of Subject Discontinuation During the Treatment Period**

Unless the subject has withdrawn consent (or the LAR has withdrawn consent on behalf of the subject) to be contacted for this study, every reasonable effort should be made to complete the ET visit and the safety follow-up (as outlined in [Table S-1](#)) if a subject discontinues prematurely for any reason. All information will be reported on the applicable pages of the electronic case report form (eCRF).

If a subject is discontinued from the study because of an AE, every reasonable attempt should be made to follow and appropriately treat the subject until the AE resolves or until the Investigator deems the AE to be chronic or stable. For subjects who continue to be followed for safety, SAEs should continue to be reported as described in [Section 7.4.2](#). All SAEs will continue to be followed and appropriately treated until such events have resolved or the Investigator deems them to be chronic or stable.

#### **4.5 Subject Lost to Follow-Up**

A subject will be considered lost to follow-up if they fail to attend a scheduled visit (excluding the safety follow-up telephone call) and the study site is unable to contact the subject or caregiver.

Every reasonable effort should be made to contact the caregiver and will include a minimum of 3 documented telephone calls and, if necessary, a certified letter to the subject's last known mailing address or local equivalent methods. All contact attempts are to be documented in the source documents.

#### **4.6 Concomitant Therapy**

In order to ensure that appropriate concomitant therapy is administered, it is essential that caregivers be instructed not to administer any medication to the subject without prior consultation with the Investigator (unless the subject is receiving treatment for a medical emergency).

The Investigator may prescribe appropriate medication to treat AEs. The Sponsor and Investigator or designee will confer to determine whether it is appropriate to continue such a subject in the trial if a prohibited medication is prescribed.

It is not necessary to make an effort to maintain stable regimens of concomitant medications and non-medicine based therapies throughout the course of the study. New medications and treatments may be initiated during the study, excluding the prohibited medications IGF-1, growth hormone, and insulin.

#### **4.6.1 Permitted and Prohibited Medications**

Prohibited medications are IGF-1, growth hormone, and insulin. Prohibitions for concomitant medications will be followed between the Baseline visit and EOT/ET visit. Medications that can prolong QT interval are not prohibited but must be used with caution. Any use of medications that could interfere with study conduct must be discussed with the Medical Monitor.

Use of medications that could interfere with study conduct or any questions regarding concomitant medications must be reviewed and/or discussed with the Medical Monitor.

Subjects who require current treatment with a prohibited medication will be withdrawn from the study.

Subjects who have previously taken a prohibited medication during the study will be withdrawn from the study unless:

- the prohibited medication has been discontinued AND
- withdrawal from the study presents an unacceptable medical risk to the subject

The justification to allow the subject to continue in the trial will be made by the Sponsor/Medical Monitor, with medical input from the Investigator, and will be documented. If a subject is allowed to remain in the trial, this will be reported as a major protocol deviation and not a waiver.

### **5 INVESTIGATIONAL PRODUCT**

#### **5.1 Investigational Product Description**

The investigational product will be trofinetide oral solution. Dose will be based on weight as outlined in [Table S–1](#). Trofinetide will be provided in a ready-to-use aqueous solution for oral administration. Doses will be administered orally or by G tube (doses administered by gastrojejunal [GJ] tubes must be administered through the G-port).

##### **5.1.1 Formulation, Appearance, and Packaging**

The Sponsor will supply trofinetide oral solution as an aqueous, ready-to-use, strawberry-flavored liquid in 500 mL (16 oz) round, high-density polyethylene (HDPE) plastic bottles with a child-resistant closure.

Trofinetide oral solution is a clear, pink to red-colored liquid containing 1 gram of trofinetide in each 5 mL. The trofinetide oral solution also contains purified water, maltitol, strawberry flavor, sucralose, methylparaben sodium, propylparaben sodium, and FD&C Red #40 as inactive ingredients.

Trofinetide is manufactured under current Good Manufacturing Practices.

During the treatment period, study drug will be distributed in a quantity sufficient to ensure the subject has an adequate supply of study drug between study visits.

### 5.1.2 Product Storage and Stability

Investigational product will be shipped refrigerated at a temperature between 2°C and 8°C (36°F and 46°F) and will be stored at this temperature. Do not freeze.

### 5.1.3 Dosing and Administration

#### 5.1.3.1 Dosing

The subject's assigned dose for this study will be the final dose from the antecedent study. If the subject's weight at the Baseline visit of the present study puts them in a new weight category (see Table 5–1), the Investigator may decide to increase the dose to the dose associated with the new weight category. Similarly, if the subject's weight after 52 weeks in the present study, or thereafter puts them in a new weight category, the Investigator may decide to increase the dose to the dose associated with the new weight category.

The dose may be decreased during the study for poor tolerability as discussed in [Section 5.1.3.2](#). Study drug is administered twice a day, once in the morning and once in the afternoon or evening. There should be at least 8 hours between doses. The study drug may be given with or without food.

**Table 5–1 Weight-Dosing Categories**

Weight	Dose	Total Daily Dose
12-20 kg	30 mL (6 g) BID	60 mL (12 g)
>20-35 kg	40 mL (8 g) BID	80 mL (16 g)
>35-50 kg	50 mL (10 g) BID	100 mL (20 g)
>50 kg	60 mL (12 g) BID	120 mL (24 g)

Abbreviation: BID=twice daily

Since all subjects in this study are known to have taken trofinetide without developing an unacceptable prolongation of the QT interval, there is no requirement to perform an ECG 2-3 hours after the first dose.

The day the first dose is taken will be considered Day 1 of dosing.

Investigational product will be shipped directly to the subject. Confirmation of any delivery to the subject will be made by a visiting nurse. Study drug shipment, return, and accountability will be performed in accordance with the drug distribution plan. In addition,

study drug will be dispensed at the site during the Baseline visit when the visit is conducted in the clinic.

#### **5.1.3.2 Administration of Study Drug**

Study drug is supplied in 500 mL (16 oz) bottles with a child-resistant closure. A press-in bottle adapter and syringe for accurately measuring the dose are supplied separately.

Doses may be taken orally or via gastrostomy tube.

- When study drug is given orally, it may be administered directly from a syringe or transferred into another container to facilitate administration.
- For gastrojejunal tubes, medication should be given via the gastric port. The tube must be flushed with water after study drug administration to clear the tube of study drug. No more than 250 mL of water should be used. Doses should be taken over a 10-minute period.

If the subject cannot tolerate administration of the full assigned dose the Investigator may instruct the caregiver to reduce study drug to a dose as low as 3 g (15 mL) BID. In addition, up to 4 doses (in total, consecutive or non-consecutive) may be held for this reason.

#### **5.1.4 Method of Assigning Subjects to Treatment Groups**

All eligible subjects will receive twice-daily doses of trofinetide over the duration of the study. Details of trofinetide dosing and administration are provided in [Section 5.1.3](#).

#### **5.1.5 Blinding**

This is an open-label study.

#### **5.1.6 Study Drug Compliance**

If a subject misses one dose of study drug, she must not take an extra dose the next day.

#### **5.1.7 Overdose**

An overdose is a deliberate or inadvertent administration of a treatment at a dose higher than the maximum recommended dose per protocol. It must be reported, irrespective of outcome, even if toxic effects were not observed ([Section 7.4.4](#)). All events of overdose are to be captured as protocol deviations. The maximum recommended dose for each subject is provided in [Section 5.1.3](#).

### **5.2 Investigational Product Accountability Procedures**

The Investigator or designee will keep current and accurate records of the study drug product dispensed, used, and returned for each subject to assure the health authority and the Sponsor that the study drug is being handled appropriately. Caregivers must be instructed to return all

packaging to the Investigator or designee at regularly scheduled clinic or home nursing visits as appropriate.

At appropriate intervals during the study, study drug reconciliation will be performed by the Sponsor (or designee) who may return appropriate unused study drug and used and unused packaging to the Sponsor's designee for destruction.

At the conclusion of the study, final study drug reconciliation will be conducted at the site. Final study drug accountability documentation will be maintained at both the site and by the Sponsor or designee. Any remaining unused study drug and all used and unused packaging will be sent back to the Sponsor's designee for destruction or destroyed at the site, as allowed by country-specific regulations. Documentation of study drug destruction will be recorded and maintained by both the Sponsor and the Sponsor's designee.

The Investigator or designee is responsible for taking an inventory of each shipment of study drug received and comparing it with the accompanying material shipping form. The Investigator or designee will verify the accuracy of the information on the form, sign and date it, and provide a copy of it to the Sponsor or designee. Any study drug supplied is for use in this study only and must not be used for any other purpose.

## **6 STUDY PROCEDURES**

Study-specific procedures are detailed below. All assessments will be completed according to the schedule described in [Table S-1](#). Every effort should be made to complete the required procedures and evaluations at the designated visits and times.

The assessments at the EOT visit of the antecedent study will serve as the Baseline assessment of the present study.

### **6.1 Efficacy Assessments**

All assessments will be administered in a standardized manner. Clinician completed measures will be completed by trained practitioners. Caregiver completed assessments will be reviewed by study personnel, and caregivers will receive standardized training and guidance on how to complete the measures. To the extent possible, all efforts should be made to maintain the same caregiver (i.e., caregiver rater) and clinician rater (as applicable) across visits for a single subject.

#### **6.1.1 Rett Syndrome Behaviour Questionnaire (RSBQ)**

The Rett Syndrome Behaviour Questionnaire (RSBQ) is a 45-item caregiver-completed rating scale assessing a wide range of neurobehavioral symptoms known to be impaired in RTT ([Mount et al. 2002](#)). The RSBQ is a well-validated instrument that has been used in the Phase 2 study, Neu-2566-RETT-002, as well as in other observational and interventional

studies in RTT (Glaze et al. 2019; Khwaja et al. 2014; O’Leary et al. 2018). The RSBQ has been correlated with functioning and quality of life and has been characterized and validated across a range of ages and genetic variations in RTT (Cianfaglione et al. 2015; 2016; Robertson et al. 2006; Barnes et al. 2015). The scale includes 45 items, including 8 subscales, whose ratings reflect the severity and frequency of symptoms. The caregiver rates items as “0” (not true), “1” (somewhat or sometimes true) or “2” (very true). The eight subscales include:

1. General mood
2. Breathing problems
3. Hand behavior
4. Face movements
5. Body rocking/expressionless face
6. Nighttime behaviors
7. Fear/anxiety
8. Walking/standing

As much as possible, caregiver raters will remain the same throughout the study.

The RSBQ assessment will be administered at Baseline and at all other designated visits.

#### **6.1.2 Clinical Global Impression–Improvement (CGI-I) and Clinical Global Impression–Severity (CGI-S)**

The CGI-I scale will be administered at Baseline and Visit 2. Completion of this scale requires the clinician to rate how much the subject’s illness has improved or worsened relative to a baseline state. A 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

The CGI-I assessed in the present study will be a comparison with the subject’s condition at the Baseline visit of the antecedent Study ACP-2566-004.

The CGI-S assessment will be made at Baseline and at all other designated visits. The CGI-S is a 7-point scale that requires the clinician to rate the severity of the subject’s illness at the time of assessment, relative to the clinician’s experience with subjects who have the same diagnosis. Considering total clinical experience, a subject is assessed on severity of illness at the time of rating: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

In this study, the illness being assessed is Rett syndrome as a whole.



Following best practice, the CGI-S and CGI-I ratings for the study will be assessed using RTT-specific anchors across major symptom areas in the same manner as in the Phase 2 studies ([Neul et al. 2015](#); [Busner and Targum 2007](#); [Glaze et al. 2017](#); [Glaze et al. 2019](#)).

### **6.1.3 Communication and Symbolic Behavior Scales - Developmental Profile Infant-Toddler (CSBS-DP-IT) Checklist**

The Communication and Symbolic Behavior Scales-Developmental Profile™ (CSBS-DP) is a standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months ([Wetherby et al. 2002](#)) and can be used with older children with developmental delay ([Anagnostou et al. 2015](#); [Urbanowicz et al. 2016](#)). The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist will be used.

Given the limited communication abilities of individuals with Rett Syndrome, the CSBS-DP-IT Checklist was assessed and a subset of items were found to be appropriate for assessing communication skills of individuals with Rett syndrome 8 to 19 years of age ([Urbanowicz et al. 2016](#)). The CSBS-DP-IT was assessed in a Phase 2 trial of mecasermin (recombinant human IGF-1) a compound related to trofinetide, in children with Rett syndrome 2 to 10 years of age ([O’Leary et al. 2018](#)). In that study, the first 16 items were completed, which allowed for calculation of the Social composite score. The CSBS-DP-IT demonstrated evidence of benefit in subjects in the active treatment group compared to those in the placebo treatment group ([O’Leary et al. 2018](#)). The CSBS-DP Social composite score has also shown evidence of sensitivity to change in behavioral intervention studies in other developmental disorders (e.g., [Wetherby et al. 2014](#); [Anagnostou et al. 2015](#)).

The CSBS-DP-IT Checklist is a 24-item rating scale completed by the caregiver. Each item is scored using a three-level rating of frequency: “not yet”, “sometimes” and “often”. Three composite scores assessing 7 skill areas can be calculated: 1) Social Composite (including Emotion and Eye Gaze, Communication Rate and Function, and Gestures); 2) Speech Composite (including Sounds and Words); 3) Symbolic Composite (including Understanding and Object Use).

All 24 items on the Infant-Toddler Checklist are to be completed by the caregiver. The question after item 24 (“Do you have any concerns about your child’s development?”) is not to be completed. At each administration, the study staff will review the instructions and scoring rubric with the caregiver. The Social Composite raw score, comprised of items 1 to 13, is used for the key secondary endpoint.

The CSBS-DP-IT Checklist will be administered at Baseline and at all other designated visits.

#### **6.1.4 The Quality of Life Rating of the Impact of Childhood Neurologic Disability (ICND) Scale**

The Impact of Childhood Neurologic Disability (ICND) Scale was developed to evaluate the impact that a child's condition has on the child's and the family's everyday life at the present time and during the previous 3 months (Camfield et al. 2003). The parent or other caregiver evaluates the effect of a condition or health problem on 11 aspects of the child's or the family's life.

The caregiver then rates overall quality of life of the subject by responding to the following: "Please rate your child's overall 'Quality of Life' on the scale below. Choose the number which you feel is best and circle it". The choices range from 1 ("Poor") to 6 ("Excellent").

In this study, the caregiver will rate only the Quality of Life assessment of the ICND Scale. The assessment will be administered at Baseline and at all other designated visits.

#### **6.1.5 Rett Syndrome Clinician Rating of Hand Function (RTT-HF)**

The Rett Syndrome Clinician Rating of Hand Function is a clinician completed clinical assessment of the subject's ability to use her hands for functional purposes (such as reaching for and grasping objects, self-feeding or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment. This rating is a further development of the RTT-DSC Hand Use Rating used in Study Neu-2566-RETT-002.

The assessment will be administered at Baseline and at all other designated visits.

#### **6.1.6 Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)**

The Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills is a clinician completed clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, climbing stairs). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment. This rating is a further development of the RTT-DSC Ambulation Rating used in Study Neu-2566-RETT-002.

The assessment will be administered at Baseline and at all other designated visits.

### **6.1.7 Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)**

The Rett Syndrome Clinician Rating of Ability to Communicate Choices is a clinician completed clinical assessment of the subject's ability to communicate her choices or preferences, which can include the use of nonverbal means such as eye contact or gestures. The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment. This rating is a further development of the RTT-DSC Language/Communication Rating used in Study Neu-2566-RETT-002.

The assessment will be administered at Baseline and at all other designated visits, when the visit takes place in the clinic. When a study visit takes place off-site, the RTT-COMC should be completed if possible, but it is not required.

### **6.1.8 Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)**

The Rett Syndrome Clinician Rating of Verbal Communication is a clinician completed clinical assessment of the subject's ability to communicate verbally (e.g., words and phrases). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment. This rating is a further development of the RTT-DSC Language/Communication Rating used in Study Neu-2566-RETT-002.

The assessment will be administered at Baseline and at all other designated visits.

### **6.1.9 Rett Syndrome Caregiver Burden Inventory (RTT-CBI)**

The RTT-CBI is a syndrome-specific, caregiver-completed questionnaire that is based on the Caregiver Burden Inventory designed for Alzheimer's disease ([Lane et al. 2017](#); [Novak and Guest 1989](#)). The scale is intended to directly address caregiver burden and indirectly assess the significance of treatment effects on function in the context of activities of daily living. Caregivers rate how often a given statement describes their feeling or experience. Frequency ratings are on a 5-point Likert scale including: 0-never; 1-rarely; 2-sometimes; 3-frequently and 4-nearly always. As in the original Caregiver Burden Inventory, the RTT-CBI has 24 negatively worded items (items 1 through 24) yielding a total score up to 96. The RTT-CBI also includes 2 positively worded items (items 25 and 26) that comprise the Optimism Index ([Lane et al. 2017](#)). The total score is defined as the total Burden score (items 1-24).

The RTT-CBI will be completed at Baseline and at all other designated visits.

## **6.2 Safety Assessments**

### **6.2.1 Physical Examination**

A general physical examination will be conducted at Baseline and at all other designated visits. When a study visit takes place off-site, the physical examination will not be required. The physical exam procedures will include the following organ systems:

- Neurological
- Head, ears, eyes, nose, and throat
- Skin
- Cardiovascular
- Respiratory
- Abdomen
- Genitourinary (optional)
- Musculoskeletal

### **6.2.2 Vital Signs**

Vital signs will include body temperature, resting respiration rate, sitting systolic and diastolic blood pressure, and pulse rate. The sitting blood pressure will be measured after the subject has been sitting for  $\geq 3$  minutes.

Vital signs to be measured at Baseline and at all other designated visits.

### **6.2.3 Height, Weight, and Body Mass Index**

Height will be measured at Baseline and all other designated visits.

Weight will be measured at Baseline and all other designated visits when the visit takes place in the clinic. When a study visit takes place off-site, weight should be measured whenever possible.

Body mass index will be calculated using the following formula:

$$\text{Weight (kg)} / [\text{height (m)}]^2.$$

### **6.2.4 Electrocardiograms**

All 12-lead ECGs will be complete, standardized recordings, whenever possible. ECGs will be completed in triplicate at Baseline before dosing, and a single ECG will be completed at all other designated visits. The ECG taken at the EOT visit in the antecedent study is the Baseline ECG of the present study. For visits at which more than one ECG is completed, the

average QTcF interval of all legible ECGs will be used to determine the QTcF interval for that visit.

The subject should rest for  $\geq 5$  minutes in a supine position before the ECG is obtained. If it is impractical to rest in supine position due to the subject's medical condition, the subject may remain in a partial supine or other position (e.g., upright in wheelchair) for  $\geq 5$  minutes before the ECG is obtained and when the ECG is obtained. ECG tracings (paper or electronic) will be reviewed and interpreted by a qualified clinician for prolongation of the QTcF interval and for other cardiac irregularities. ECG tracings and results (ventricular rate, PR, QRS, QT, QTcF and QTcB intervals) will be included in the subject's study records.

At Baseline, the average QTcF interval of all legible ECGs will be used to determine eligibility. A reasonable effort should be made to obtain three ECGs. If it is not feasible or if completing two or three ECGs demands extraordinary effort, the clinician may stop and document the reason for not obtaining the three ECGs. The ECGs that have been completed and are legible should be transmitted to central ECG reader. ECGs will be read by a qualified central reader. The central reading will be the reading that is entered in the database. The results from the reports from the central reader will be reviewed by the Investigator.

#### **6.2.4.1 Post-Enrollment QTcF Interval Stopping Criteria**

In the event that a post-enrollment QTcF duration of  $\geq 500$  ms or an increase of  $\geq 60$  ms compared to the average QTcF interval at Baseline of the present study (before dosing) is observed, study drug administration is to be discontinued. For visits at which more than one ECG is completed, the average QTcF interval of all legible ECGs will be used to determine the QTcF interval for that visit.

#### **6.2.5 Laboratory Evaluations**

Laboratory evaluations will be completed according to the schedule presented in [Table S-1](#) and procedures detailed in the laboratory manual. Additional safety testing may be performed at the discretion of the Investigator or designee.

Clinical laboratory sample collection is not required to be completed under fasting conditions. The laboratory evaluations will include the following:

- Clinical chemistry serum tests
  - Sodium (Na), potassium (K), chloride (Cl), phosphorus (P), calcium (Ca), carbon dioxide (CO<sub>2</sub>), blood urea nitrogen (BUN), creatinine (CR), uric acid
  - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), total bilirubin (TBIL), lactate dehydrogenase (LDH)

- Glucose
- Albumin (ALB), total protein
- Pregnancy test
  - A serum pregnancy test will be performed at all designated visits ([Table S–1](#)) for subjects of childbearing potential
- Hematology tests
  - Complete blood count (CBC) including:
    - White blood cell (WBC) count
    - Complete differential (relative and absolute)
    - Hematocrit (Hct), hemoglobin, red blood cells (RBC), platelets
    - Reticulocyte count
- Urinalysis
  - Blood, RBCs, WBCs, protein, glucose, ketones, specific gravity, pH
  - Reasonable efforts will be made to collect a urine sample from all subjects. When collection of a urine sample proves impractical or impossible (e.g., because the subject is incontinent or unable to cooperate), failure to collect a urine sample will be recorded in the subject's eCRF, and will not be considered a protocol deviation

### 6.3 Caregiver Diary

A semi-structured caregiver diary will be completed during treatment in which caregivers will record seizures and seizure-like spells if they are present.

At the Baseline visit, the clinician will review subject's seizure profile (if applicable) and will, if necessary, update the characterization of the subject's typical seizure types. These are recorded in the caregiver diary. Dose modifications and missed or partial doses will be recorded in the caregiver diary.

The caregiver diary will be completed and collected on an ongoing basis throughout the study from Baseline to EOT/ET. The clinician will verbally ask about AEs (see [Section 7.4.1](#)), review the events recorded in the diary with the caregiver and will make a clinical evaluation, including an evaluation of whether an AE will be reported.

### 6.4 Caregiver Interview

An optional qualitative interview with caregivers of study subjects will be conducted remotely by telephone. Only caregivers of subjects for whom separate informed consent for

the caregiver interview is completed will be interviewed. Interviews will be conducted by trained moderators from a 3<sup>rd</sup> party and are anticipated to be approximately up to 60 minutes in duration. The interviews are planned to elicit a better understanding of the observable signs as well as the impact of study drug and RTT both on the study subject and on the caregiver. The interviews will document changes observed by the caregivers over the course of participation in the study and in antecedent trofinetide studies. The interviews will also provide an opportunity to describe the meaningfulness of any improvements that may have occurred from the perspective of the caregiver. Interviews will be audio-recorded and transcribed for analysis. Any personally identifiable health information mentioned during the interview will be redacted by the interviewer prior to transcription of the interview. Furthermore, if any potential adverse events are revealed during the interview, the interviewer will inform the investigator of the potential adverse event. Audio recordings of the interviews will be destroyed following transcription.

Following the analysis of the qualitative data, a summary report that describes the objectives, methods, participants, and results of the qualitative interviews will be prepared and reported separately from the clinical study report.

The caregiver interview will be administered at or before the final study visit (Week 130 [EOT/ET]).

## **7 ADVERSE EVENTS**

### **7.1 Specification of Safety Parameters**

#### **7.1.1 Definition of Adverse Event**

An AE is defined as “any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study drug, whether or not considered related to study drug”.

An AE can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality or seriousness. An AE can arise from any use of the drug (e.g., off-label use, use in combination with another drug) and from any route of administration, formulation, or dose, including an overdose.

A suspected adverse reaction is any AE for which there is a reasonable possibility that the drug caused the AE.

AEs do not include the following:

- Stable or intermittent chronic conditions (such as myopia requiring eyeglasses) that are present prior to Baseline and do not worsen during the study

- Medical or surgical procedures (e.g., surgery, endoscopy, tooth extraction, transfusion). The condition that leads to the procedure is an AE if not present at Baseline.
- Overdose of concomitant medication without any signs or symptoms unless the subject is hospitalized for observation; if an overdose occurs, it will be reported on an overdose form
- Hospitalization for elective surgery planned prior to study (situation where an untoward medical occurrence has not occurred)
- Pregnancy will not be considered an AE, but if it occurs, it will be reported on a pregnancy form

### **7.1.2 Definition of Serious Adverse Event**

In addition to the severity rating, each AE will be classified by the Investigator as “serious” or “not serious.” The seriousness of an event will be defined according to the applicable regulations and generally refers to the outcome of an event. An SAE is one that meets one or more of the following:

- Is fatal
- Is immediately life threatening
- Results in disability or permanent damage
- Requires hospitalization
- Prolongs existing hospitalization
- Is a congenital anomaly or birth defect (in an offspring)
- Is medically significant

### **Definition of Life Threatening**

A life-threatening event places the subject at immediate risk of death from the event as it occurred. This does not include an AE, which, had it occurred in a more severe form, might have caused death.

### **Definition of Hospitalization**

Hospitalization is defined by the Sponsor as a full admission to the hospital for diagnosis and treatment. This includes prolongation of an existing inpatient hospitalization.

Examples of visits to a hospital facility that do **not** meet the serious criteria for hospitalization include:



- Emergency room visits (that do not result in a full hospital admission)
- Outpatient surgery
- Preplanned or elective procedures
- Protocol procedures
- Social hospitalization, defined as admission to the hospital as a result of inadequate family support or care at the subject's primary residence

### **Definition of Disability or Permanent Damage**

Disability is defined as a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.

### **Definition of Medically Significant**

Important medical events (medically significant events) that may not result in death, be life threatening, or require hospitalization may be considered to be an SAE when, based upon appropriate medical judgment, they may jeopardize the subject or may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization or development of drug dependency or drug abuse.

An SAE may also include any other event that the Investigator or Medical Monitor judges to be serious or that suggests a significant hazard, contraindication, side effect, or precaution.

## **7.2 Classification of an Adverse Event**

### **7.2.1 Severity of Event**

The severity of each AE will be graded on a 3-point scale and reported in detail as indicated on the eCRF:

- **Mild:** awareness of sign or symptom but easily tolerated, causing minimal discomfort, and not interfering with normal everyday activities
- **Moderate:** sufficiently discomforting to interfere with normal everyday activities
- **Severe:** incapacitating and/or preventing normal everyday activities

### **7.2.2 Relationship to Study Drug**

The causality of each AE should be assessed and classified by the Investigator as "related" or "not related." An event is considered related if there is a reasonable possibility that the event

may have been caused by the product under investigation (i.e., there are facts, evidence, or arguments to suggest possible causation).

**Consider the following when assessing causality:**

- Temporal associations between the agent and the event
- Response to cessation (de-challenge) or re-challenge
- Compatibility with known class effect
- Known effects of concomitant medications
- Pre-existing risk factors
- A plausible mechanism
- Concurrent illnesses

**7.2.3 Duration**

The start and stop dates for AEs will be recorded using the following criteria:

- **Start:** Date of the first episode of the AE or date of significant sustained worsening in severity
- **Stop:** Date when AE either ceased permanently or changed in severity

For AEs of diarrhea, the start date and stop date of a decrease in severity will also be recorded.

**7.2.4 Frequency**

The frequency of the AE should be indicated according to the following definitions:

- **Single:** Experienced once, without recurrence
- **Recurrent:** More than one discrete episode with the same severity

**7.2.5 Action Taken with Study Drug**

- **Dose not changed:** No change in study drug
- **Drug interrupted:** Study drug temporarily stopped
- **Drug withdrawn:** Study drug discontinued permanently
- **Dose decreased:** Dose of study drug reduced

**7.2.6 Therapy**

- **None:** No new treatment instituted

- **Medication:** New treatment initiated as a direct result of AE
- **Other:** Other action required

#### 7.2.7 Outcome

- **Recovered/resolved:** Recovered or resolved
- **Recovered/resolved with sequelae:** Recovered or resolved with sequelae
- **Not recovered/not resolved:** Not recovered or not resolved
- **Fatal:** Death due to an AE
- **Unknown:** Unknown

#### 7.2.8 Seriousness

- **Not serious**
- **Serious** (see [Section 7.1.2](#))

#### 7.2.9 Definition of Unexpectedness

An AE, the nature or severity of which is not consistent with the information provided in the Reference Safety Information section of the current trofinetide Investigator's Brochure.

### 7.3 Time Period and Frequency for Event Assessment and Follow-Up

Adverse events with an onset before the first dose of open-label trofinetide in the present study will be recorded as an AE in the antecedent study. All ongoing AEs from the antecedent trofinetide study will be carried over after informed consent has been obtained for the present study and recorded from Baseline for the present study until resolution or the follow-up safety assessment. An adverse event occurring after the first dose of open-label trofinetide in the present study will be recorded as an AE in the present study. Adverse events for the present study will be recorded from the time of first dose of open-label trofinetide in the present study through the safety follow-up period.

All AEs must be either resolved or stable at the end of the safety follow-up period. If an AE is ongoing at the end of the study safety follow-up period, every reasonable attempt should be made to follow and appropriately treat the subject until the AE resolves or until the Investigator deems the AE to be chronic or stable.

In the event that a subject discontinues and has an ongoing AE at the time of discontinuation ([Section 4.4.2](#)) or is withdrawn from the study because of an AE, the subject should be followed and appropriately treated until the AE resolves or until the Investigator deems the AE to be chronic or stable.

## **7.4 Reporting Procedures**

### **7.4.1 Adverse Event Reporting**

The Investigator must record all observed AEs and all reported AEs. At each visit, the Investigator should ask the subject a nonspecific question (e.g., “Have you noticed anything different since your last visit?”) to assess whether any AEs have been experienced since the last report or visit.

Note that any use of medication (and specifically any newly prescribed medication) during the course of a study may indicate the occurrence of an AE that may need to be recorded on both the AE and the concomitant medication page.

All AEs, serious and not serious, will be recorded on the AE eCRF page using appropriate medical terminology. Severity and relationship to study drug will be assessed by the Investigator.

When possible, clinical AEs should be described by diagnosis and not by symptoms (e.g., “cold” or “seasonal allergies” instead of “runny nose”).

All AEs, *whether or not related to the study drug*, must be fully and completely documented on the AE eCRF and in the subject’s notes.

### **7.4.2 Serious Adverse Event Reporting**

The reporting of SAEs by the Sponsor or designee to the regulatory authorities is a regulatory requirement. Each regulatory authority has established a timetable for reporting SAEs based upon established criteria.

Serious AEs must be reported within 24 hours of discovery to the Sponsor or its designee; use the appropriate form for initial and/or follow-up reporting.

At a minimum, events identified by the Sponsor to require expedited reporting as serious, unexpected, and related to study drug must be brought to the attention of the responsible institutional review board/ethics committee (IRB/EC), as per applicable regulations. These will be provided by the Sponsor after their assessment. For European Union member states, the Sponsor or its designee will provide reports of suspected unexpected serious adverse reactions (SUSARs) directly to the ECs, as required by local legislation. In all other countries, it is the Investigator’s responsibility to provide these expedited reports to the responsible IRB/EC. It is also the Investigator’s responsibility to notify the responsible IRB/EC regarding any new and significant safety information.

When an SAE occurs, Investigators will review all documentation related to the event and will complete the paper SAE form with all required information (for initial and/or follow-up

information) and fax or email (within 24 hours of discovery) to the contact information provided on the SAE form.

Subjects will be followed through the safety follow-up period (i.e., 30 [+4] days after last dose of study drug) for any SAEs and/or other reportable information until such events have resolved or the Investigator deems them to be chronic or stable.

In the event of any SAE (other than death), the study subject will be instructed to contact the Investigator (or designee) using the telephone number provided in the informed consent form (ICF). All subjects experiencing an SAE will be seen by the Investigator or designee as soon as is feasible following the report of the SAE.

Serious AEs occurring after the study follow-up period (i.e., 30 [+4] days after last dose of study drug) should be reported if in the judgment of the Investigator there is “a reasonable possibility” that the event may have been caused by the product.

SAEs should also be reported to the IRB/EC according to local regulations.

#### **7.4.3 Reporting of Pregnancy**

Any subject who becomes pregnant during the study (with or without AEs) must be withdrawn from the study and the pregnancy must be reported on the Pregnancy form within 24 hours of discovery to the Sponsor or its designee. Any subject who becomes pregnant during the study will be followed through the pregnancy outcome.

Any AEs that are the consequence of pregnancy and which meet the criteria for serious should also be reported via the SAE form.

##### **7.4.3.1 Reporting Paternal Drug Exposure**

Paternal drug exposure is defined as a father’s exposure to a medicinal product before or during his partner’s pregnancy. Any paternal drug exposure cases must be reported to the Sponsor within 24 hours of discovery via the Pregnancy form. Any AEs that are the consequence of paternal drug exposure and which meet the criteria for serious must also be reported to the Sponsor within 24 hours of discovery via the SAE form. Since no males are enrolling in this study, paternal drug exposure would occur only if a male who was not a study subject ingested study drug.

#### **7.4.4 Reporting of Overdose**

An overdose is a deliberate or inadvertent administration of a treatment at a dose higher than the maximum recommended dose per protocol. It must be reported to the Sponsor or designee on the Overdose form within 24 hours of discovery. In addition, all events of overdose are to be captured as protocol deviations.

## **8 CLINICAL MONITORING**

Routine monitoring of study sites is described in [Section 11](#).

Clinical site monitoring is conducted to ensure that the rights and well-being of human subjects are protected, that the reported study data are accurate, complete, and verifiable, and that the conduct of the study is in compliance with the currently approved protocol and amendment(s) as applicable, with GCP, and with applicable regulatory requirements. Details of the study site monitoring process are described in a separate clinical monitoring plan document.

## **9 STATISTICAL METHODS AND DATA ANALYSIS**

### **9.1 Statistical and Analytical Plans**

Statistical methods will be documented in detail in a statistical analysis plan (SAP) to be approved by the Sponsor prior to database lock.

### **9.2 Statistical Hypotheses**

No formal testing of hypotheses is planned; all outcomes will be summarized descriptively.

### **9.3 Sample Size Determination**

The sample size of this open-label study is not determined based on statistical considerations. However, subjects enrolled in the present study are those who have completed the antecedent study, ACP-2566-004, and rolled over to the present study. Since approximately 180 subjects are to be enrolled in the ACP-2566-004 study and it is expected 85% of these subjects will complete Study ACP-2566-004 and rollover to the present study, the number of subjects in the present study will be approximately 153.

### **9.4 Subject Populations for Analysis**

The Safety Analysis Set will include all subjects who received at least one dose of study drug in this study. This analysis set will be used for all safety as well as any descriptive efficacy analyses.

### **9.5 Statistical Analyses**

#### **9.5.1 General Approach**

All endpoints will be summarized for the Safety Analysis Set.

Data from the EOT visit procedures of Study ACP-2566-004 will be carried over as Baseline information in the present study, as applicable, (e.g., not for the CGI-I).

Continuous measurement results will be reported using the number of subjects with data values, mean, standard error of the mean, median, standard deviation, minimum, and

maximum. For each categorical outcome, the frequency and percentage of subjects in each category will be reported.

### **9.5.2 Primary Analyses**

Adverse events will be classified into standard terminology using the Medical Dictionary for Regulatory Activities (MedDRA). All AEs will be listed and TEAEs will be summarized by system organ class and preferred term. A TEAE is defined as an AE that started after the first administration of study drug and no later than the last administration of study drug plus 30 days. Summaries by maximum severity and by relationship to study drug will also be provided. Serious TEAEs, fatal AEs, and TEAEs leading to discontinuation will also be summarized.

Descriptive summary statistics for ECG, vital signs and body weight, and clinical laboratory parameters, including observed values and changes from Baseline, will be tabulated by timepoint. Additionally, categorical analyses will be conducted on the incidence of subjects with prolonged QTc intervals and changes in QTc intervals in accordance with International Council for Harmonisation (ICH) guidelines.

### **9.5.3 Efficacy Analyses**

Descriptive summary statistics for RSBQ (absolute values and change from Baseline), CGI-I (absolute values, assessed by comparing to the status at Study ACP-2566-004 baseline), CGI-S, CSBS-DP-IT, each of the four Rett Syndrome Clinician Rating scales, RTT-CBI, and ICND Quality of Life score absolute values and change from Baseline will be summarized by timepoint.

### **9.5.4 Subgroup Analyses**

Selected analyses may be performed in subgroups. Details will be provided in the SAP.

## **9.6 Interim Analyses**

No interim analysis is planned in this study.

## **9.7 Measures to Minimize Bias**

Not applicable. The present study is open label.

## **9.8 Breaking the Study Blind/Subject Code**

Not applicable. The present study is open label.

## **10 STUDY MANAGEMENT AND DATA COLLECTION**

### **10.1 Data Collection and Management Responsibilities**

All documents required for the conduct of the study as specified in the ICH GCP guidelines will be maintained by the Investigator in an orderly manner and made available for monitoring and/or auditing by the Sponsor and regulatory authorities.

The Investigator and institution must permit authorized representatives of the Sponsor or designees (including monitors and auditors), regulatory authorities (including inspectors), and the IRB/EC direct access to source documents (such as original medical records). Direct access includes permission to examine, analyze, verify, and reproduce any records and reports that are needed for the evaluation of the study. The Investigator must ensure the reliability and availability of source documents from which the information on the eCRF was derived.

### **10.2 Source Documents**

All study specific information obtained at each study visit must be recorded in the subject's record (source documentation), and then entered into a validated electronic data capture (EDC) database by trained site personnel. The source documentation may consist of source notes captured by site personnel and the caregiver diaries, as well as laboratory reports, ECG reports, and electronic source data.

### **10.3 Case Report Forms**

Subject data required by this protocol are to be recorded in an EDC system on eCRFs. The Investigator and his or her site personnel will be responsible for completing the eCRFs. The Investigator is responsible for the accuracy and reliability of all the information recorded on the eCRFs. All information requested on the eCRFs needs to be supplied, including subject identification data, visit date(s), assessment values, etc., and any omission or discrepancy will require explanation. All information on eCRFs must be traceable to source documentation at the site.

### **10.4 Confidentiality**

The Investigator must ensure that each subject's anonymity is maintained as described below. On the eCRFs, medical records, and other documents submitted to the Sponsor or designees, subjects must be identified by a subject identification number only. Subject identifiers uniquely identify subjects within the study and do not identify any person specifically. Documents that are not for submission to the Sponsor or designees (e.g., signed ICFs) should be kept in strict confidence by the Investigator in compliance with Federal regulations or other applicable laws or ICH guidance on GCP. Data collection and handling should comply



with the European Union General Data Protection Regulation (EU GDPR), where applicable. Acadia has assigned a Data Protection Officer (DPO) as per the EU GDPR.

### **10.5 Study Records Retention**

Investigators are required to maintain all essential study documentation as per ICH GCP guidelines. This includes, but is not limited to, copies of signed, dated and completed eCRFs, documentation of eCRF corrections, signed ICFs, subject-related source documentation, and adequate records for the receipt and disposition of all study drug. Investigators should maintain all essential study documentation, for a period of at least 2 years following the last approval of marketing application in an ICH region (US, Europe, and Japan), or until at least 2 years after the drug investigational program is discontinued, unless a longer period is required by applicable law or regulation. Only the Sponsor can notify an Investigator or vendor when any records may be discarded. Investigators should contact the Sponsor before destroying any files.

### **10.6 Protocol Exceptions and Deviations**

No prospective entry criteria protocol deviations are allowed; all subjects must meet all eligibility criteria in order to participate in the study. Subjects with major eligibility protocol deviations identified in the antecedent study are not eligible for the present study even if the subject was allowed to continue in the antecedent study.

Protocol waivers for eligibility will not be granted by the Sponsor under any circumstances. If, during the course of a subject's post-enrollment participation in the trial it is discovered that the subject did not meet all eligibility criteria, this will be reported as a major protocol deviation and not a waiver. In this situation, the subject will be discontinued, unless the discontinuation presents an unacceptable medical risk. The justification to allow the subject to continue in the trial will be made by the Sponsor, with medical input from the Investigator, and will be documented. If allowed to remain in the trial, this will be reported as a major protocol deviation and not a waiver. All follow-up safety assessments must be completed and documented as outlined in the protocol ([Section 3.1.2](#)). The Investigator must report any protocol deviation to the Sponsor and, if required, to the IRB/EC in accordance with local regulations, within reasonable time.

### **10.7 Protocol Amendments**

Changes to the protocol may be made only by the Sponsor (with or without consultation with the Investigator). All protocol modifications must be submitted to the site IRB/EC in accordance with local requirements and, if required, to regulatory authorities, as either an amendment or a notification. Approval for amendments must be awaited before any changes can be implemented, except for changes necessary to eliminate an immediate hazard to trial

subjects, or when the changes involve only logistical or administrative aspects of the trial. No approval is required for notifications.

## **11 QUALITY MANAGEMENT**

### **11.1 Risk Management**

The Sponsor utilizes the ICH E6 (GCP) Revision 2 risk management approach that includes methods to assure and control the quality of the trial proportionate to the risks inherent in the trial and the importance of the information collected. The intent is that all aspects of this trial are operationally feasible and that any unnecessary complexity, procedures, and data collection are avoided. The Sponsor's risk management approach includes the following documented activities with a focus on data and processes critical to ensure human subject protection and the reliability of trial results:

- Risk Identification: risks to critical trial processes, governing systems, investigational product, trial design, data collection, and recording are identified.
- Risk Evaluation: identified risks are evaluated by considering the following factors: (a) likelihood of occurrence, (b) impact on human subject protection and data integrity, and (c) detectability of errors.
- Risk Control: risks that can be avoided, reduced (i.e. mitigated) or accepted are differentiated. Risk mitigation activities are incorporated in protocol design and implementation, study plans, training, processes, and other documents governing the oversight and execution of study activities. Where possible, predefined quality tolerance limits are defined to identify systematic issues that can impact subject safety or data integrity and deviations from the predefined quality tolerance limits will trigger an evaluation and possibly an action. Contingency plans are developed for issues with a high risk factor that cannot be avoided.
- Periodic risk review, communication, and escalation of risk management activities are ongoing during trial execution and risk outcomes are reported in the clinical study report (CSR).

### **11.2 Quality Control and Quality Assurance**

The Sponsor or designees and regulatory authority inspectors are responsible for contacting and visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial (e.g., eCRFs and other pertinent data) provided that subject confidentiality is respected.

The Sponsor's or designee's monitor is responsible for inspecting the eCRFs at regular intervals throughout the study to verify adherence to the protocol; completeness, accuracy,

and consistency of the data; and adherence to local regulations on the conduct of clinical research. The monitor should have access to subject medical records and other study-related records needed to verify the entries on the eCRFs.

The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved.

In accordance with ICH guidance on GCP and the Sponsor's audit plans, sites participating in this study may be audited. These audits may include a review of site facilities (e.g., pharmacy, drug storage areas, and laboratories) and review of study-related records may occur in order to evaluate the trial conduct and compliance with the protocol, ICH guidance on GCP, and applicable regulatory requirements.

The Sponsor's or designee's representatives, regulatory authority inspectors and IRB/EC representatives who obtain direct access to source documents should also respect subject confidentiality, taking all reasonable precautions in accordance with applicable regulatory requirements to maintain the confidentiality of subjects' identities.

## **12 ETHICAL CONSIDERATIONS**

### **12.1 Ethical Standard**

The study will be conducted in compliance with the protocol, the Declaration of Helsinki, ICH GCP, and other applicable regulatory requirements (e.g., Serious Breach reporting, urgent safety measures, and EU GDPR).

The study will be performed in accordance with the US Health Insurance Portability and Accountability Act (HIPAA) regulations, US FDA GCP Regulations (US Code of Federal Regulations [CFR] 21 parts 50, 54, 56, and 312), and ICH guidance on GCP (E6) and clinical safety data management (E2A).

In accordance with Directive 75/318/EEC, as amended by Directive 91/507/EEC, the final clinical study report will be signed by an Investigator and/or Coordinating Investigator who will be designated prior to the writing of the clinical study report.

### **12.2 Institutional Review Board/Ethics Committee**

The Investigator or designee will provide the IRB/EC with all requisite material, including a copy of the protocol, informed consent, and any subject information or advertising materials. The study will not be initiated until the IRB/EC provides written approval of the protocol and the informed consent and until approved documents have been obtained by the Investigator and copies received by the Sponsor. All amendments will be sent to the IRB/EC for information (minor amendment) or for submission (major amendment) before implementation. The Investigator will supply the IRB/EC and the Sponsor with appropriate

reports on the progress of this study, including any necessary safety updates, in accordance with the applicable government regulations and in agreement with policy established by the Sponsor.

### **12.3 Informed Consent Process**

In accord with the provisions of the US CFR 21 part 50, and since this study involves greater than minimal risk but presents the prospect of direct benefit to all subjects enrolled, consent shall be obtained from an LAR, typically a guardian, or at least one parent, in accordance with local IRB requirements. Minors will be given the opportunity to assent to participation if and when they are considered capable of doing so by the PI and per local IRB requirements.

Properly executed, informed consent/assent must be obtained from each LAR/subject prior to the final procedures being performed at the EOT visit in the antecedent study. The LAR is defined as “An individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject’s participation in the procedures involved in the research” (US CFR 21 part 50).

For subjects who are minors, written informed consent will be obtained from the LAR. For subjects who are not minors, written informed consent will be obtained from the LAR or the subject if deemed able by the Investigator. When consent is being provided by an LAR, subject assent for participation should be documented, when possible. Assent is the affirmative agreement to participate in the research of a minor or of an adult who does not have the capacity to consent. If written assent is not possible, verbal assent is allowed and must be documented. If subject assent is not possible, then the site must document rationale for not being able to provide written or documented subject assent.

If a subject’s 18th birthday takes place during the study and the subject is deemed able to consent by the Investigator, the subject should sign the informed consent. Reconsenting should take place if required by and in accordance with IRB or EC policy and applicable local law.

The subject’s caregiver must also provide informed consent regarding their participation in the study prior to participating in any study procedures.

The informed consent must, at a minimum, include the elements of consent described in the ICH guidance on GCP and the US CFR 21 part 50.25. A copy of the ICF planned for use will be reviewed by the Sponsor or designee for acceptability and must be submitted by the Investigator or designee together with the protocol, to the appropriate IRB/EC for review and approval prior to the start of the study at that investigational site. Consent forms must be in a language fully comprehensible to the LAR of the prospective subject. The Investigator must

provide the Sponsor or designee with a copy of the IRB/EC letter approving the protocol and the ICF before the study drug supplies will be shipped and the study can be initiated.

The consent form must be revised if new information becomes available during the study that may be relevant to the subject's willingness to continue participation. Any revision must be submitted to the appropriate IRB/EC for review and approval in advance of use.

### **12.3.1 Consent and Other Informational Documents Provided to Subjects**

The subject/LAR must be given a copy of the signed informed consent and the original maintained in the designated location at the site.

### **12.3.2 Consent Procedures and Documentation**

It is the Investigator or designee's responsibility to obtain written informed consent from the subject/LAR after adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. The LAR must be given ample time to decide about study participation and opportunity to inquire about details of the study. The IRB/EC-approved consent form must be personally signed and dated by the LAR with subject assent, if possible, and by the person who conducted the informed-consent discussion. The Investigator or appropriate site personnel must document the details of obtaining informed consent in the subject's study documents.

The subject's caregiver must also indicate their understanding of the study and their role as a caregiver to the subject during the study. The subject's caregiver must provide written consent prior to any study procedures being performed indicating their agreement to participate in the study in the caregiver role.

Participation in the caregiver interview is optional. Informed consent must be obtained by the Investigator (or designee), as appropriate, prior to the interviewer contacting the caregiver and conducting the optional caregiver interview.

Where applicable and permitted, informed consent forms may be administered remotely in accordance with ICH E6 and applicable regulations.

Records related to a study subject's participation will be maintained and processed according to local laws, and where applicable, the European Union General Data Protection Regulation (EU GDPR). The consent and study information documentation will include statements describing local and regional requirements concerning data privacy, and who to contact for questions.

### **13 PUBLICATION PLAN**

All publication rights are delineated in the Clinical Study Agreement and/or other separate agreements with the Investigator and/or Institution, as applicable.

### **14 CONFLICT OF INTEREST POLICY**

#### **14.1 Finance, Insurance, and Indemnity**

Arrangements for finance, insurance, and indemnity are delineated in the Clinical Study Agreement and/or other separate agreements with the Investigator and/or Institution, as applicable.

## 15 LITERATURE REFERENCES

Anagnostou E, Jones N, Huerta M, et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. *Autism*. 2015;19(5):622-36.

Barnes KV, Coughlin FR, O'Leary HM, et al. Anxiety-like behaviour in Rett syndrome: characteristics and assessment by anxiety scales. *J Neurodev Disord*. 2015;7(1):30.

Bienvenu T, Philippe C, De Roux N, et al. The incidence of Rett syndrome in France. *Pediatr Neurol*. 2006;34(5):372-375.

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. *Psychiatry*. 2007;4(7):28-37.

Byiers BJ, Symons FJ. Issues in estimating developmental level and cognitive function in Rett syndrome. In: Hodapp RM ed. *International Review of Research in Developmental Disabilities*. Waltham, MA: Elsevier Inc.; 2012;43:147-185.

Camfield C, Breau L, Camfield P. Assessing the impact of pediatric epilepsy and concomitant behavioral, cognitive, and physical/neurologic disability: impact of Childhood Neurologic Disability Scale. *Dev Med Child Neurol*. 2003;45(3):152-159.

Cass H, Reilly S, Owen L, et al. Findings from a multidisciplinary clinical case series of females with Rett syndrome. *Dev Med Child Neurol*. 2003;45(5):325-337.

Cianfaglione R, Clarke A, Kerr M, et al. A national survey of Rett syndrome: behavioural characteristics. *J Neurodev Disord*. 2015;7(1):11.

Cianfaglione R, Clarke A, Kerr M, Hastings RP, Oliver C, Felce D. Ageing in Rett syndrome. *J Intellect Disabil. Res*. 2016;60(2):182-190.

Clarkson T, LeBlanc J, DeGregorio G, et al. Adapting the Mullen Scales of Early Learning for a standardized measure of cognition in children with Rett syndrome. *Intellect Dev Disabil*. 2017;55(6):419-431.

Djukic A, McDermott MV. Social preferences in Rett syndrome. *Pediatr Neurol*. 2012;46(4):240-242.

Downs J, Bebbington A, Jacoby P, et al. Level of purposeful hand function as a marker of clinical severity in Rett syndrome. *Dev Med Child Neurol*. 2010;52(9):817-823.

Downs J, Bebbington A, Kaufmann WE, Leonard H. Longitudinal hand function in Rett syndrome. *J Child Neurol*. 2011;26(3):334-340.

Epstein A, Leonard H, Davis E, et al. Conceptualizing a quality of life framework for girls with Rett syndrome using qualitative methods. *Am J Med Genet A*. 2016;170(3):645-653.

- Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. *Neurology*. 2019;92(16):e1912-e1925.
- Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. *Pediatr Neurol*. 2017;76:37-46.
- Hite KC, Adams VH, Hansen JC. Recent advances in MeCP2 structure and function. *Biochem Cell Biol*. 2009;87(1):219-227
- ICH Harmonized Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. October 1994.
- Iemmi V, Knapp M, Brown FJ. Positive behavioural support for children and adolescents with intellectual disabilities whose behaviour challenges: an exploration of the economic case. *J Intellect Disabil*. 2016;20(3):281-295.
- Ip JPK, Mellios N, Sur M. Rett syndrome: insights into genetic, molecular and circuit mechanisms. *Nat Rev Neurosci*. 2018;19(6):368-382.
- Kaufmann WE, Tierney E, Rohde CA, et al. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. *J Intellect Disabil Res*. 2012;56(3):233-247.
- Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. *Eur Child Adolesc Psychiatry*. 1997;6 Suppl 1:71-74.
- Khwaja O, Ho E, Barnes KV, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. *Proc Natl Acad Sci. U.S.A.* 2014;111(12):4596-4601.
- Kriaucionis S, Bird A. DNA methylation and Rett syndrome. *Hum Mol Genet*. 2003;12 Spec No 2:R221-227.
- Lane J, Salter A, Jones NE, et al. Assessment of Caregiver Inventory for Rett syndrome. *J Autism Dev Disord*. 2017;47(4): 1102-1112.
- Larsson G, Lindström B, Engerström IW. Rett syndrome from a family perspective: the Swedish Rett Center survey. *Brain Dev*. 2005;27 Suppl 1:S14-19.
- Lee JY, Leonard H, Piek JP, Downs J. Early development and regression in Rett syndrome. *Clin Genet*. 2013;84(6):572-576.
- Motil KJ, Caeg E, Barrish JO, et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. *J Pediatr Gastroenterol Nutr*. 2012;55(3):292-298.



- Mount RH, Charman T, Hastings RP, Reilly S, Cass H. Features of autism in Rett syndrome and severe mental retardation. *J Autism Dev Disord*. 2003;33(4):435-442.
- Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. *J Child Psychol Psychiatry*. 2002;43(8):1099-1110.
- Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Behavioural and emotional features in Rett syndrome. *Disabil Rehabil*. 2001;23(3-4):129-138.
- Neul JL, Benke TA, Marsh ED, et al. The array of clinical phenotypes of males with mutations in methyl-CpG binding protein 2. *Am J Med Genet B Neuropsychiatr Genet*. 2019;180(1):55-67.
- Neul JL, Glaze D, Percy A, et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression scale. *J Child Neurol*. 2015;30(13):1743-1748.
- Neul JL, Lane JB, Lee HS, et al. Developmental delay in Rett syndrome: data from the natural history study. *J Neurodevelop Dis*. 2014;6:20.
- Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. *Ann Neurol*. 2010;68(6):944-950.
- Neul JL, Fang P, Barrish J, et al. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. *Neurology*. 2008;70(16):1313-1321.
- Novak M, Guest C. Application of a multidimensional Caregiver Burden Inventory. *Gerontologist*. 1989;29(6):798-803.
- O'Leary HM, Kaufmann WE, Barnes KV, et al. Placebo controlled crossover efficacy assessment of mecamermin for the treatment of Rett syndrome. *Ann Clin Transl Neurol*. 2018;5(3):323-332.
- Palacios-Ceña D, Famoso-Pérez P, Salom-Moreno J, et al. "Living an obstacle course": A qualitative study examining the experiences of caregivers of children with Rett syndrome. *Int J Environ Res Public Health*. 2018;16(1):41.
- Percy AK, Lane J, Annese F, Warren H, Skinner SA, Neul JL. When Rett syndrome is due to genes other than MECP2. *Transl Sci Rare Dis*. 2018;3(1):49-53.
- Percy AK, Lee HS, Neul JL, et al. Profiling scoliosis in Rett syndrome. *Pediatr Res*. 2010;67(4):435-439.
- Perry A, Sarlo-McGarvey N, Haddad C. Brief report: cognitive and adaptive functioning in 28 girls with Rett syndrome. *J Autism Dev Disord*. 1991;21(4):551-556.

Robertson L, Hall SE, Jacoby P, Ellaway C, de Klerk N, Leonard H. The association between behaviour and genotype in Rett syndrome using the Australian Rett Syndrome Database. *Am J Med Genet.* 2006;141B(2):177-183.

Rose SA, Djukic A, Jankowski JJ, Feldman JF, Fishman I, Valicenti-McDemott M. Rett syndrome: an eye-tracking study of attention and recognition memory. *Dev Med Child Neurol.* 2013;55(4):364-371.

Samaco RC, Neul JL. Complexities of Rett syndrome and MeCP2. *J Neurosci.* 2011;31(22):7951-7959.

Thompson RH, Iwata BA. A descriptive analysis of social consequences following problem behavior. *J Appl Behav. Anal.* 2001;34(2):169-178.

Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. *Proc Natl Acad Sci U S A.* 2009;106(6):2029-2034.

Urbanowicz A, Downs J, Girdler S, Ciccone N, Leonard H. An exploration of the use of eye gaze and gestures in females with Rett syndrome. *J Speech Lang Hear Res.* 2016;59(6):1373-1383.

Urbanowicz A, Downs J, Girdler S, Ciccone N, Leonard H. Aspects of speech language abilities are influenced by *MECP2* mutation type in girls with Rett syndrome. *Am J Med Genet.* 2015;167A(2):354-362.

West PR, Amaral DG, Bais P, et al. Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children. *PLoS One.* 2014;9(11):e112445.

Wetherby AM, Guthrie W, Woods J, et al. Parent-implemented social intervention for toddlers with autism: an RCT. *Pediatrics.* 2014;134(6):1084-1093.

Wetherby AM, Allen L, Cleary J, Kublin K, Goldstein H. Validity and reliability of the communication and symbolic behavior scales developmental profile with very young children. *J Speech Lang Hear Res.* 2002;45(6):1202-1218.

Woodyatt GC, Ozanne AE. A longitudinal study of cognitive skills and communication behaviours in children with Rett syndrome. *J Intellect Disabil Res.* 1993;37(Pt 4):419-435.

Yasui DH, Xu H, Dunaway KW, Lasalle JM, Jin LW, Maezawa I. MeCP2 modulates gene expression pathways in astrocytes. *Mol Autism.* 2013;4(1):3.

Young DJ, Bebbington A, Anderson A, et al. The diagnosis of autism in a female: could it be Rett syndrome? *Eur J Pediatr.* 2008;167(6):661-669.